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RÉSUMÉ 
 
 Dans ce mémoire, je présente mes études sur la synthèse, la caractérisation et l’évaluation biologique 
de différentes séries d’analogues du D-heptapeptide appelé 101.10, un modulateur négatif allostérique du 
récepteur de l’interleukine-1β (IL-1β). Sachant que les peptides ont généralement de faibles propriétés 
pharmacologiques, le but de ce projet portait sur l’examen des structures nécessaires à la bioactivité, la 
conformation tridimensionnelle de ces derniers afin d’améliorer la droguabilité du peptide parent.  
 Les stratégies d’optimisation du 101.10 utilisées furent : la coupure N- et C-terminale; la substitution par 
la proline, α-amino-γ-lactame (Agl), β-amino-γ-lactame (Bgl) et α-amino-β-hydroxy-γ-lactame (Hgl); et la 
rigidification du squelette à l’aide d’un bicycle, l’indolozidin-2-one (I
2
aa). Afin de clarifier certaines relations de 
structure-activité, quelques modifications furent apportées au peptide, incluant l’échange de la thréonine pour la 
valine, la permutation de la stéréochimie de certains résidus clés ainsi que le remplacement de certaines chaînes 
latérales par un méthyle. Pour pallier aux difficultés de reproductibilité des résultats avec des échantillons 
provenant de différentes sources, des études sur l’identité du contre-anion et la pureté du peptide furent 
conduites. 
 Afin d’évaluer l’effet des modifications sur la conformation aqueuse et l’activité biologique du peptide, 
des analyses de dichroïsme circulaire et des tests in vitro mesurant l’inhibition de certains effets de l’IL-1β furent 
effectués. Ces essais cellulaires comportaient l’inhibition de la prolifération de cellules immunes et de l’activation 
des voies de signalisation inflammatoires du facteur nucléaire κB (NF-κB) et de la protéine kinase activée par 
mitogène (MAPK), toutes deux stimulées par l’IL-1β. La compilation de ces données a permis de déceler 
certaines tendances entre la structure, la conformation et l’activité anti-IL-1β des peptidomimétiques.  
 
 
 
 
 
 
 
ii 
 
MOTS CLÉS 
 
Inflammation, interleukine-1β, mime peptidique, amino-gamma-lactame, indolizidinone, structure secondaire de 
peptide, repliement bêta, prolifération de thymocytes, activation du facteur nucléaire kappaB et de la protéine 
kinase activée par mitogène, contre-anion. 
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ABSTRACT 
 
 In this thesis, I present my studies toward the synthesis, characterisation and biological evaluation of 
different series of analogues of the D-heptapeptide called 101.10, a negative allosteric modulator of the 
interleukin-1β (IL-1β) receptor. Considering that peptides generally exhibit poor pharmacological properties, the 
objective of this project consisted in: the examination of the peptidic structures essential to elicit bioactivity; the 
investigation of the three-dimensional arrangement of these moieties; and the improvement of the “drug-like” 
properties of the parent peptide.  
 The optimisation strategies that were used include: N- and C-terminal truncation; positional scanning 
using monocycles such as proline, α-amino-γ-lactam (Agl), β-amino-γ-lactam (Bgl) and α-amino-β-hydroxy-γ-
lactam (Hgl); and backbone rigidification with indolizidin-2-one (I
2
aa). Moreover, in order to validate certain 
structure-activity relationships, further modifications were performed on the peptide: substitution of threonine for 
valine, exchange of stereochemistry, and substitution of certain side-chain for a methyl group. Lastly, due to 
divergent behaviour between peptide samples obtained from different sources, studies on the identity of the 
counter-anion and on the sample purity were conducted.  
 In order to evaluate the influence of these modifications on the aqueous conformation and on the 
biological activity of the peptide, circular dichroism analyses and in vitro tests measuring the inhibition of certain 
IL-1β-mediated effects were performed. These cellular assays comprised the inhibition of IL-1β-stimulated 
proliferation of immune cells, as well as activation of the inflammatory pathways of nuclear factor κB (NF-κB) and 
mitogen-activated protein kinase (MAPK) pathways. Compiling these data revealed certain trends existing 
between the structure, conformation and anti-IL-1β activity of the peptidomimetics.  
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CHAPTER 1 
Introduction 
 
 
Chapter 1 2 
 
1.1 Interleukin-1β 
1.1.1 Cytokines  
 Cytokines are small (generally 5 to 30 kDa; Vilcek, 2006) signaling molecules that regulate the 
mammalian immune system. Cytokines are commonly designated as inflammatory “hormones”, because they are 
secreted by a broad variety of cells and possess auto-, endo- and paracrine actions with potency comparable to 
other peptide hormones. Of the numerous families of cytokines known, the interleukin-1 (IL-1) superfamily is 
primarily associated with acute and chronic bouts of inflammation (Gabay et al., 2010; Dinarello, 2011). Initially, 
IL-1 was designated by several terms, each one referring to a biological effect observed by a given laboratory 
(Dinarello, 1994). Subsequently, two forms of the cytokine were individually cloned in the 1980s (March et al., 
1985), and a more structure-oriented classification of IL-1 was established; however, confusion still arises from 
the multiple appellations given to the newly discovered family members by different laboratories. In the new 
millennium, a standardised nomenclature was proposed in which the term IL-FX is used and X corresponds to 
the form (F) number (Sims et al., 2001).  
 
1.1.2  IL-1 superfamily 
 The IL-1 superfamily includes eleven distinct members. The principal members are IL-1α, IL-1β, IL-1Ra, 
IL-18 and IL-33, which share close genomic and proteomic similarities (Dinarello, 2011). For example, the 
encoding regions of IL-1α and IL-1β are located side by side on the human chromosome 2 (Webb et al., 1986). In 
spite of having only 27% amino acid sequence homology, IL-1α and IL-1β both adopt a similar tertiary 
conformation (Priestle et al., 1989; Graves et al., 1990) made of twelve β-strands arranged into a single opening 
six-stranded-barrel, sometimes called a β-trefoil (Figure 1.1). Typical of most IL-1 family members, IL-1α and IL-
1β impart similar physiological effects but have different cellular localization patterns as well as distinct 
mechanisms of maturation and secretion. Both of these IL-1 forms are produced mainly by stimulated monocytes 
as well as macrophages (Dinarello, 1994), and to a lesser extent by multiple other cell types, including 
neutrophils, keratinocytes, epithelial and endothelial cells, lymphocytes, smooth muscle cells, fibroblasts and 
certain melanomas. Although both cytokines are synthesized as 31 kDa precursor peptides, only the pro-IL-1α 
has intrinsic activity (Mosley et al., 1987; Black et al., 1988). Mature IL-1α is constitutively secreted in primary 
cells, anchored primarily into the cytosolic membrane and signals through autocrine or juxtacrine mechanisms 
(Brody et al., 1989; Weber et al., 2010). On the other hand, pro-IL-1β is cleaved by an enzyme known as 
caspase-1 (or IL-1-converting enzyme, ICE) and secreted through unconventional pathways (Gabay et al., 2010; 
Weber et al., 2010). IL-1β is the predominantly secreted form of IL-1. 
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Figure 1.1. The β-trefoil structure of IL-1β (β-sheets are shown in red, coil in magenta and α-helices in cyan) 
(PDB ID 2I1B, Priestle et al., 1989). 
 
1.1.3 IL-1 Receptors 
 Members of the IL-1 family of receptors contain activators and suppressors of inflammation. The 
physiological effects of IL-1 are mediated through binding to the IL-1 type I receptor (IL-1RI) (Sims et al., 1988). 
The type II receptor (IL-1RII) functions as a decoy receptor, which inhibits triggering of IL-1-related pathways 
(Colotta et al., 1994). In spite of minimal amino acid homology, the structure of all IL-1 receptor family members 
displays either one or three immunoglobulin (Ig)-like folds. For example, IL-1RI contains three such Ig-like 
extracellular domains as well as a cytoplasmic domain that shares some homology with other members of the 
IL‑1R and Toll-like receptor (TLR) families, the so-called Toll‑like/IL-1R (TIR) domain (Dunne et al., 2003; 
Subramaniam et al., 2004). An Ig fold features two β-pleated sheets fixed by intradomain disulfide bonds 
between conserved cysteine residues (Subramaniam et al., 2004). Upon binding of IL-1β to IL-1RI, the receptor 
undergoes a conformational change which allows recruitment of a second receptor chain, called the IL-1 receptor 
accessory protein (IL-1RAcP) (Greenfeder et al., 1995). Assembled together, the IL-1β/IL-1RI/IL-1RAcP complex 
forms the heterodimeric signaling trigger (Figure 1.2). Although most cell types express ubiquitously IL-1RI, 
expression of IL-1RAcP is not constitutive in some cells (Dinarello, 2009). By consequence, not all cell types 
expressing IL-1RI are able to activate the various IL-1-related signaling pathways. 
  
Figure 1.2. Crystal structure of cytosolic IL-1R complex (IL-1RI is shown in magenta, IL-1RAcP in cyan and IL-1β 
in green; PDB ID 3O4O; Wang et al., 2010). 
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1.1.4  IL-1β-mediated signaling pathways 
 There exist numerous IL-1β-related intracellular signaling pathways (Weber et al., 2010). Herein, a 
simplified version of the canonical signaling cascade is described (Figure 1.3). First, in response to the formation 
of the IL-1β/IL-1RI/IL-1RAcP ternary complex, a mosaic of combinatorial phosphorylation and ubiquitination 
events are triggered. These ultimately result in the activation of nuclear factor (NF)-κB signaling, as well as 
initiation of pathways mediated by the extracellular signal‑regulated kinase (ERK), c-Jun N-terminal kinase (JNK) 
and p38 mitogen-activated protein kinase (MAPK). These pathways cooperatively induce the expression of 
canonical IL-1 target genes (notably IL-6, IL-8, MCP-1, COX-2, IκBα, IL-1α, IL-1β, MKP-1) by transcriptional and 
posttranscriptional mechanisms. Of note, most intracellular components that partake in the cellular response to 
IL-1 also mediate responses to other cytokines (IL-18, IL-33 and other IL-1 family members), TLRs and many 
forms of cytotoxic stresses.  
 
Figure 1.3. Main IL-1β signaling pathways (adapted from Dinarello, 2009). Common abbreviations: IL-1β, 
interleukin-1β; IL-1RI, IL-1 receptor type I; IL-1RAcP, IL-1R accessory protein; IL-1RII, IL-1 receptor type II; 
MyD88, myeloid differentiation primary response gene 88; Tollip, toll-interacting protein; IRAK-1, IL-1 receptor-
associated kinase 1; TRAF-6, TNF receptor associated factor 6; TAK1, transforming growth factor-β-activated 
kinase 1; TAB1, TAK1-binding protein; IκB,  IkappaBα and IkappaBβ complex; IKKβ, IκB kinase; NF-κB, nuclear 
factor kappaB; p38 MAPK, p38 mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase. The asterisk (*) 
denotes phosphorylated proteins.  
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1.1.5 Physiological roles 
 The primary function of IL-1-type cytokines is to control proinflammatory reactions in response to 
detection of pathogen- and danger-associated molecular patterns (PAMPS and DAMPS, respectively) (Weber et 
al., 2010). IL-1-type cytokines are therefore considered major mediators of innate immune reactions. In particular, 
IL-1β is considered as a primary proinflammatory mediator, because it is expressed by many different cellular 
types and partakes in numerous signaling pathways leading to expression of inflammatory factors. Depending on 
the cascade activated, IL-1β may stimulate a broad variety of physiological effects (Dinarello, 1997): metabolic, 
inflammatory, immunologic, physiologic and hematologic. In brief, IL-1β induces the production of nitric oxide 
(NO), cyclooxygenase (COX)-2, prostaglandin E2 (PGE2), intercellular adhesion molecule-1 (ICAM-1), 
metalloproteinases (MMP-1), growth factors (GM-CSF, VEGF), cytokines (IL-1β and TNF-α), chemokines and 
hematopoietic factors (fibrinogen, PAF). The sum of these factors will ultimately lead to hyperthermia, 
hypotension, tissue destruction, hematopoiesis, triggering of innate and adaptive immune responses and 
inflammation.  
 
1.1.6  IL-1β-related diseases 
 By virtue of its various physiologic effects, a slight imbalance in IL-1β frequently leads to pathogenetic 
conditions. For example, IL-1β plays a major role in a wide range of inflammatory, autoinflammatory and 
autoimmune diseases. These include, but are not restricted to, rheumatoid arthritis (RA), osteoarthritis (OA), 
chronic obstructive pulmonary disease (COPD), asthma, inflammatory bowel disease (IBD), atherosclerosis, 
cryopyrin-associated periodic syndrome (CAPS), family mediterranean fever (FMF),  as well as diseases of the 
central nervous system such as multiple sclerosis (MS), Alzheimer’s disease and stroke (Lachmann et al., 2011; 
Dinarello, 2011). In recent years, research has unveiled other potential IL-1β-related indications, such as 
pericarditis, type 2 diabetes (T2D) and smoldering multiple myeloma (SMM), a hardly curable form of bone 
cancer (Gabay et al., 2010). In sum, IL-1β has emerged as an important therapeutic target for an expanding 
number of systemic and local inflammatory conditions.  
 
1.2  Targeting IL-1β 
 With greater knowledge of the key physiologic and pathogenetic roles of IL-1β, several endogenous 
inhibitors have been identified and numerous targeting agents have been developed. The main anti-IL-1β 
strategies are briefly described below. 
 1.2.1  Endogenous IL‑1β inhibitors  
 There exist several natural inhibitors of IL-1β, including IL-1Ra, IL-1RII, single immunoglobulin IL-1R-
related molecule (SIGIRR), soluble receptors and signaling inhibitors (Figure 1.4) (Gabay et al., 2010). Several 
studies have substantiated that the balance between proinflammatory versus anti-inflammatory cytokines affects 
the severity of inflammatory diseases. Therefore, maintenance of a tight balance between IL-1β and its 
endogenous regulators is critical to avoid excessive inflammatory responses (Arend, 2002).  
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Figure 1.4. Natural inhibitors of IL-1 (Dinarello, 2011). 
 IL-1Ra was the first competitive antagonist to a cytokine receptor to be described in the literature (Arend 
1985). The key regulatory role of IL-1Ra was demonstrated using IL-1Ra-knockout mice, which developed 
excessive inflammatory responses and spontaneous skin and joint inflammation (Ma et al., 1998; Horai et al., 
2000). Notably, children deficient in IL-1Ra suffer more from autoinflammatory disease (Gabay 2009). Although 
IL-1Ra possesses a β-trefoil structure similar to that of IL-1β, it lacks the loop between β-strands 4 and 5, which 
is essential for agonistic action (Dunn et al., 2003b). IL-1Ra is therefore a competitive inhibitor of IL1-RI, with 
near equal affinity as IL-1β. However, a 100- to 1000-fold excess of IL-1Ra is needed to competitively block IL-1 
activity both in vitro and in vivo (Dinarello et al., 1991). 
 IL-1RII lacks the cytoplasmic TIR domain necessary for initiating intracellular signaling (Colotta et al., 
1994). By consequence, IL-1RII binding to IL-1β and subsequent recruitment of the accessory protein forms a 
non-signaling complex which efficiently sequesters IL-1β at the membrane. Moreover, IL-1β binds to IL-1RII with 
a greater affinity than IL-1α and IL-1Ra (Smith et al., 2003). Therefore, IL-1RII acts as a dominant negative 
modulator of the IL-1β-dependent signaling.  
 SIGIRR belongs to the IL-1R family, but possesses a single extracellular Ig-like domain and an 
additional 100 amino acid C-terminal tail (Qin et al., 2005; Gabay et al., 2010). Although no ligands were clearly 
identified for SIGIRR, its TIR domain is known to inhibit activation of NF-κB, ERKs and JNKs by trapping the 
signaling molecules TRAF6 and IRAK-1 (Qin et al., 2005). The extracellular portion of SIGIRR is also suspected 
to interfere with the heterodimerization of IL-1RI and IL-1RAcP (Qin et al., 2005).  
 In addition to their membrane-bound forms, soluble receptors (sIL-1RI, sIL-1RII and sIL-1RAcP) are 
readily released by cells and bind to IL-1 in this microenvironment, preventing it from mediating cellular activity. 
Binding of IL-1β to sIL-1RII is nearly irreversible, due to a slow dissociation rate, whereas sIL-1RAcP enhances 
the binding affinity of both IL-1α and IL-1β to sIL-1RII (Smith et al., 2003), and can form an inactive complex with 
surface-expressed IL-1RI bound to IL-1. A neuronal-specific splice variant of IL-1RAcP, termed IL-1RAcPb, has 
been shown to form a complex with IL-1RI, without leading to recruitment of MyD88 and IRAKs (Smith et al., 
2009). 
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1.2.2  Anti-IL-1β therapies      
 Numerous avenues for anti-IL-1β therapy have been exploited by the pharmaceutical industry during the 
past 15 years (Dumont, 2006, Braddock et al., 2004, Dinarello et al., 1991). Although many have served as tools 
in experimental models of inflammation, few have been tested in clinical trials, and only three have been 
approved by the Food and Drug Administration of the USA (FDA). The following paragraphs summarize the main 
anti-IL-1β inhibitors, in accordance with their mode of action. 
 
1.2.2.1  Inhibition of IL-1β production 
 Blockers of IL-1β production may target its transcription, processing or release. A popular approach 
adopted by companies to impede IL-1β processing (Figure 1.5) has been to inhibit caspase-1, also called IL-1-
converting enzyme (ICE) due to its ability to cleave off pro-IL-1β into its mature form. Orally active ICE inhibitors 
have been investigated in humans (Dumont, 2006). These include peptidomimetics of an active tetrapeptide (Ac-
Tyr-Val-Ala-Asp-CHO) (Thornberry et al., 1994), namely the pyridiazopinedione Pralnacasan (1.1, Rudolphi et al., 
2003), the constrained tert-glycyl-proline analog (1.2, VX-765, Stack et al., 2005) and the quinoxaline mimetic 
SNS-11 (1.3, O’Brien et al., 2005) (Figure 1.6). The purinergic receptor P2X7R has also been targeted to 
antagonize IL-1β processing and release, because of its involvement in the ATP-dependent activation of ICE and 
the secretion of IL-1β. Blockers of P2X7R include adamantane AZD-9056 (1.4, Chambers et al., 2010) and 
diarylimidazolines SAR-7b (1.5, Merriman et al., 2005). Two fungal metabolites, the terpenoid lactone LL-Z1271α 
(1.6, Ichikawa et al., 2001) and the picolinate CJ-14,877 (1.7, Ichikawa et al., 2001b; Perregaux et al., 2001), as 
well as pyridazines such as K-832 (1.8, Tabunoki et al., 2003) displayed IL-1 production inhibition, albeit with 
unknown mechanisms of action.  
 
Figure 1.5. Main inhibitors of IL-1β production (adapted from Kopf et al., 2010). 
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Figure 1.6. Structure of small anti-IL-1β molecules.  
 
1.2.2.2  Inhibition of IL-1β action 
 After IL-1β is secreted in the extracellular environment, its action can be antagonized by neutralising IL-
1β itself or by blocking its receptor (Figure 1.7). As discussed in the previous section, IL-1β can be neutralized by 
binding to soluble receptors, such as sIL-1RI, sIL-1RII and sIL-1RAcP (Smeets et al., 2003), which have higher 
affinity for the cytokine than membrane-bound forms. Phase I clinical studies with shIL-1RII indicated a 
bioavailability (f) of 65% and a serum half-life (t½) of 58 hours when administered subcutaneously in 28 patients 
affected by rheumatoid arthritis (Caldwell, 2002). A fusion protein consisting of the two extracellular portions of IL-
1RII and IL-1RAcP bound to the crystallisable fragment (Fc) of an IgG, termed IL-1 trap, has been developed to 
sequester IL-1β and IL-1α (Guller et al., 2001). Several antibodies have been raised against IL-1β and IL-1RI, 
including Hu007 (Bright et al., 2003; Bright et al., 2005), AAL160 (Gram et al., 2001), ACZ-885 (Gram et al., 
2002) and XOMA052 (Owyang et al., 2011), which are IL-1β-specific humanised antibody without cross reactivity 
with IL-1α or IL-1Ra. The murine monoclonal antibodies AF201 and MAB201 (Witte, 2003) both inhibit the 
interaction of IL-1RAcP with IL-1β/IL-1RI. Using a murine autoimmunisation protocol, linear and cyclic peptides 
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corresponding to murine IL-1β regions which come in close proximity to IL-1RI upon binding, have been delivered 
as immunogens, which produce significant levels of neutralising antibodies against the native murine IL-1β 
(Geraghty et al., 2005). The same protocol is under investigation to elicit hIL-1β neutralising antibodies in 
humans. 
 
Figure 1.7. Main antagonists of IL-1β action (adapted from Kopf 2010). 
 Pharmaceutical companies have also worked to directly block IL-1R. Multiple studies evaluating gene 
therapy using retroviral constructs encoding human IL-1Ra are currently underway in patients afflicted with RA 
(Nita 1996). Synthetic antagonists, such as recombinant hIL-1Ra (Furst 2004) and the uncosapeptide AF10847 
(Brandhuber 2004) have prevented IL-1β binding to IL-1RI by occupying the binding site. In both cases, failure to 
interact with the second binding site located in the third Ig-like receptor domain prevented initiation of signaling. 
Fully human anti-IL-1RI and anti-IL-1RAcP mAbs have been described. The former, AMG108 (Cardiel 2010; 
Varnum 2009), targeted the third Ig domain of IL-1RI, blocking the binding of IL-1β to the receptor without 
interfering with that of IL-1Ra.  
 
1.2.2.3  Inhibition of IL-1β signaling 
 Once IL-1β has bound to IL-1RI and formed its receptor complex with IL-1RAcP, the signaling cascades 
are activated. Inhibitors of IL-1β signaling may thus interfere with several molecular targets. For example, the 
genes encoding the primary effector protein, MyD88, have been targeted with antisense oligonucleotides 
(Vickers 2006). The spiropyrrolothiazin-6-one ST-2825 (1.9, Loiarro 2007) inhibited IL-1β-induced effects both in 
vitro and in vivo, presumably by mimicking the loop of the TIR domain of IL-1RI. NF-κB activation has been 
blocked using mimetics of truncated IRAK-4 proteins, as well as the synthetic D-decapeptide RDP-58 (Travis 
2005), which correspond to the interface between IRAK-1 and TRAF-6. Other primary targets which yielded anti-
IL-1β activity include p38 MAPK and IKK-2 inhibitors: however, because numerous components of IL-1β 
signaling are shared with those of TLRs and the receptors of other cytokines, such approach may lack specificity.   
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1.2.3  FDA-approved anti-IL-1 biologics 
 Of the numerous strategies developed to antagonize IL-1β, the three which have been approved by the 
FDA are biologics sharing common characteristics: similar mode of action, mode of administration and profile of 
adverse effects (Figure 1.8).  
 
Figure 1.8. Representative crystal structures of FDA-approved anti-interleukin biologics (IL-1Ra: PDB ID 1ILR, 
Schreuder et al., 1995; IL-1 trap: PDB ID 3O4O, Wang et al., 2010; IL-1 mAb: PDB ID 3I2C, Teplyakov et al., 
2010). 
 
1.2.3.1  Anakinra 
 Anakinra (Kineret®; Amgen, USA) is a 17.3 kDa recombinant protein of the natural human IL-1R 
antagonist (hIL-1Ra), which differs from the native unglycosylated protein by the addition of an N-terminal 
methionine residue. It was approved by the FDA in 2001 to treat the signs and symptoms of rheumatoid arthritis. 
Daily injections are needed to sustain the therapeutic effect of anakinra because the average half-life is between 
4 and 6 hours and a large excess of drug is needed to block the effect of IL-1β (Furst, 2004). Consequently, this 
anti-IL-1 therapy engenders unwanted side effects such as moderate injection-site reactions, increased risk to 
Gram-positive bacterial infection, immunogenicity and neutropenia (Amgen Product monography, 2008). The 
annual cost for an adult patient is evaluated to US$ 18,180 (Kapur et al., 2009). 
 
1.2.3.2  Rilonacept 
 IL-1 trap (Rilonacept or Arcalyst®; Regeneron, USA) is a dimeric fusion protein composed of the Fc 
fraction of human IgG coupled to the extracellular binding motifs of IL-1RI and IL-1RAcP. This technology, which 
is also in use to trap IL-4, IL-13 and vascular endothelial growth factor (VEGF), works by sequestering the 
cytokine. Rilonacept was approved by the FDA in 2008 to treat the cryopyrin-associated periodic syndrome 
(CAPS), and has received the orphan drug approval for familial cold auto-inflammatory syndromes (FCAS) and 
the Muckle-Wells syndrome (MWS) in adults and children aged 12 years or older. This treatment is administered 
weekly through subcutaneous injections, and has an average annual cost of US$ 360,000 (Kapur et al., 2009). In 
a significant number of patients, Rilonacept induces moderate injection-site reactions, respiratory infections, 
colitis, gastrointestinal bleeding, and immunogenicity (FDA, 2008). 
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1.2.3.3 Canakinumab 
 Canakinumab (Ilaris®; Novartis, Switzerland) is a fully human monoclonal antibody against IL-1β, 
weighing 145 kDa. It was approved by the FDA in 2009 to treat patients suffering from the orphan disease CAPS, 
and more recently from systemic-onset juvenile idiopathic arthritis (SoJIA). This treatment costs approximately 
US$ 96,000 annually (Whalen et al., 2011; P&T, 2009), and must be administered either intravenously or 
subcutaneously, every eight weeks (Dhimolea, 2010). Canakinumab has a half-life of 28 to 30 days and a 
bioavailability of 70% (Dhimolea, 2010). Canakinumab has been shown to cause certain adverse effects, such as 
mild injection-site reactions, increased risk to infections and higher occurrence of vertigo (Dhimolea, 2010).  
 
1.2.3.4  Summary 
 Therapeutic successes have been achieved with three FDA-approved anti-IL-1β molecules, albeit with 
several drawbacks due to their appreciable size and weak “drug-like” properties. As biologics, they are relatively 
expensive and must be injected regularly. Moreover, they completely abrogate IL-1β action, including the desired 
effects of the cytokine, such as the triggering of the innate immune response, which may impoverish the host 
defence against microorganism infections. Prolonged IL-1β blockade may also promote the development of 
insulin resistance, promoting the development of T2D (Somm et al., 2006). Canakinumab, rilonacept and 
anakinra are biomacromolecules, which may contain immunogenic epitopes in their sequences. Over time, host 
organisms may thus produce neutralising antibody against these drugs, necessitating higher doses to attain the 
same therapeutic effect with higher risks of toxicity. In summary, there remains a clear and unmet medical need 
to produce small absorbable IL-1R antagonists. 
 
1.3  Our problematic 
1.3.1 Small IL-1β antagonists 
 Although small inhibitors of IL-1R have so far been difficult to generate, they would offer an appreciable 
number of therapeutic advantages compared to large biologics, such as an improved pharmacokinetic (ADMET) 
profile. Properties such as light molecular weight, small polar surface area and lower hydrophilicity could improve 
enteral bioavailability and permit oral administration. Moreover, small molecules are generally more protease 
resistant, which may prolong duration of action by diminishing metabolism and excretion. They may additionally 
present lower risk of immunogenicity and toxicity, due to weaker reactivity with enzymes and immune sensors. 
Small antagonists may likely be more affordable to produce. In addition to benefiting from improved properties 
related to their size, small IL-1R antagonists may also take advantage of the key features of an allosteric 
modulator, as discussed below. 
 
1.3.2 Allosteric IL-1R modulators 
1.3.2.1 Allosteric modulators 
 Allosteric modulators are ligands that modify protein responses to agonists, inhibitors and substrates 
upon binding (Goodey et al., 2008). Allosteric modulators, by definition, bind to a protein at a site discrete from 
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the natural substrate binding site, referred to as the orthosteric site. Three general types of allosteric modulators 
are described in drug discovery: positive, neutral and negative. Upon binding, positive allosteric modulators 
(PAM) augment the orthosteric ligand effect, neutral allosteric modulators have no observable effect on protein 
function, and negative allosteric modulators (NAM) usually inhibit the natural ligand action.  
 Both multi-subunit and monomeric proteins (i.e., receptors and enzymes) can be subjected to allosteric 
modulation. In contrast to the classical “two-state” concept, receptors are presently thought to exist in a dynamic 
state, represented by an ensemble of conformers (Hall et al., 2000). Upon binding of a ligand, local and systemic 
conformational changes may occur, leading to a variation in the thermodynamic equilibrium of conformers. 
Ligands may bind preferably to certain receptor forms, and thereby drive the conformational equilibrium toward a 
“preferred” state (Burgen, 1966). Modulation of the conformational equilibrium may therefore alter receptor 
activity and influence protein function.  
 
1.3.2.2 Allostery versus orthostery 
 Several advantages may be achieved in developing allosteric modulators as therapeutic drugs (Kenakin 
et al., 2004). For example, an allosteric modulator may demonstrate functional selectivity (or biased 
signalisation), exhibiting different biological effects depending on the orthosteric ligand utilized, and blocking or 
activating selectively certain signaling pathways while not affecting others. Moreover, an allosteric modulator has 
a saturable effect on its molecular target, such that an excess of this drug would augment duration of action 
without affecting maximum potency. Allosteric modulators may show subtype specificity, because they may bind 
at discrete sites, which differ between isoforms. These key characteristics of allosteric modulators may thus 
confer lower toxicity, higher selectivity and increased specificity. 
 
1.3.2.3 The IL-1R system and allosteric modulation 
 Allosteric modulation of IL-1R by a small antagonist may have beneficial features. For example, 
allosteric modulator may circumvent issues of inhibiting primary immune responses to microorganism invasion, 
which may occur using competitive inhibitors that intercept all IL-1 signalisation. A negative allosteric modulator 
to the IL-1R complex may thus block certain pathways that lead to pathologic signals and conserve others that 
participate in essential immunological functions. Subtype-specific modulators may also prevent inhibition of the 
soluble and alternatively spliced isoforms of the receptor and accessory protein, key natural IL-1β-regulators. 
Along these lines, a 75 kDa recombinant protein of the major extracellular portion of the IL-1RAcP demonstrated 
in vivo efficacy in a model of autoimmune arthritis without interfering with all IL-1RI-exerted actions (Smeets et 
al., 2005). 
 
1.3.3 Peptides as small IL-1R allosteric modulators   
1.3.3.1 Interface peptides  
Among many strategies to modulate receptor activity, the “interface peptide” approach (Zutshi et al., 
1996; Peczuh et al., 2000) employs a receptor-derived amino acid sequence to inhibit the inter-domain or 
protein-protein interactions of the receptor. By interfacing via insertion into an appropriate part of the receptor 
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itself or via interaction with the subunit, such peptides may displace the equilibrium of conformers and alter 
biological functions. Such “interface” peptides may be generated using a process termed peptide scanning 
(Eichler, 2008), in which short synthetic peptides are based on the protein sequence in a systematic manner 
which maps sections of the protein using overlapping fragments. Subsequent biological analysis of the peptides 
allows identification of the regions of the protein responsible for ligand recognition and activity. Such peptides 
may later serve to develop non-peptidic structures which inhibit the same inter-domain or protein-protein 
interactions. 
 
1.3.3.2 Successful examples of interface peptides in drug development 
 Among successful interface peptides, a short peptide derived from the sixth transmembrane domain of 
human β2-adrenergic receptor (β2AR) inhibited homodimerization of the receptor, which could not be inhibited by 
usual means (SDS, DDT or MR), and blocked adrenergic agonist-promoted stimulation of adenylyl cyclase 
activity (Hebert et al., 1996). Likewise, from a library of one- and two-strand peptides, candidates were identified 
which affected the assembly of proteases 1 and 2 of human immunodeficiency virus 1 (HIV-1), and prevented 
viral maturation (Babé et al., 1992; Zutshi et al., 1997). Octameric peptides were designed specifically to target 
the dimer interface of human thymidylate synthase (hTS) (Figure 1.9), a homodimeric enzyme that plays a key 
role in DNA synthesis and is a primary target in anticancer therapy. The peptides bound at a previously unknown 
allosteric site on hTS, causing inhibition of the intracellular enzyme, thereby reducing cellular growth in both 
cisplatin-sensitive and -resistant ovarian cancer cells (Cardinale et al., 2011). 
 
Figure 1.9. Allosteric peptide (red) binding to the interface of a hTS dimer (blue and green) (PDB ID 3N5E, 
Cardinale et al., 2011). 
 
1.3.3.3 Peptides as drugs    
 Peptides display notable advantages as drug candidates (Vlieghe et al., 2010). Compared to proteins 
and antibodies, peptides possess a diminished immunogenic potential, lower manufacturing costs, greater 
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stability during storage, and better organ and tumour penetration, resulting in an ameliorated biodistribution. 
Therapeutic peptides may also offer benefits over small organic molecules, including: greater efficacy, selectivity 
and specificity; minimized system toxicity caused by their safer metabolites (amino acids); reduced 
bioaccumulation owing to their short half-life and greater structural diversity.   
 Nonetheless, peptides are generally considered to possess limited clinical potential due to their intrinsic 
physicochemical properties, as interpreted using Lipinski’s rule of five (Lipinski et al., 2004), supplemented by the 
rules of Veber et al. (Veber et al., 2002). Peptides may have relatively poor drug-like properties including low oral 
bioavailability (oftenly requiring parenteral administration), short half-life owing to rapid degradation by proteolytic 
enzymes contained in the digestive and circulatory systems, rapid hepatic and renal clearances, poor ability to 
cross physiological barriers caused by their large size and hydrophilicity, and high conformational flexibility, 
occasionally resulting in off-target interactions. Peptides may thus be good entry points in a drug pipeline; 
however, chemical modification strategies may be necessary to improve their pharmacokinetic properties, 
particularly when a good enteral absorption is desired such as in cases of chronic inflammatory diseases. 
Along these lines, peptides have been employed to modulate IL-1R, because peptides are generated 
based on receptor fragments, facilitating analysis of the target interaction at the level of individual amino acid, 
and because their amino acid residues are subject to a wide variation of inter- and intramolecular interactions 
(dipole-dipole, saline bridges, H-bonds, van der Waals) to favor multiple peptide-protein binding modes. 
Furthermore, chemical methodology of peptides is well developed and may enable convenient and fast 
diversification of the scaffold. Finally, natural and short peptides are generally less toxic and immunogenic than 
their smaller organic and large biologic counterparts, respectively. 
 
1.4  Peptide mimicry 
1.4.1 Basis of peptide mimicry 
Peptide mimicry has been used to circumvent issues associated with natural peptides as drug 
candidates. Peptidomimetics (peptide mimics) may be designed to replicate the natural peptide three-
dimensional (3D) arrangement of pharmacophores, to retain the affinity for biological targets and to produce 
analogous biological effects as the parent peptide. Peptide mimic development requires identification of 
structure-activity relationships (SARs) to define the minimal active sequence (MAS) and the major 
pharmacophore elements responsible for activity (Vagner et al., 2008). Conformational constraints may then be 
applied to probe the topography of the key peptide structural features. Typical modifications employed by 
medicinal chemists to optimize a natural peptide through peptide mimicry are described in the following sections.  
 
1.4.2 Chemical strategies in peptide mimicry 
In the absence of spectroscopic and X-ray crystallographic data concerning the structure of ligand–
receptor complexes, the conformation and pharmacophore responsible for the function of the peptide may be 
elucidated by examination of the activities of various analogues. Such studies may provide an elaborated view 
point for understanding the form employed for the activity of the natural peptide, as well as valuable leads for 
building peptide mimics with enhanced physiological properties. 
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1.4.2.1 Truncation and analysis of global chirality 
 A lead peptide may be truncated one residue at a time, from the N- and C-termini, in order to find the 
MAS, which is desired because shorter peptides reduce the synthetic effort to generate successive analogues 
and simplify the analysis of their analogue-receptor interactions. Thereafter, the significance of configuration and 
sequence orientation may be probed by Ret design (Ret or retro-enantio; Goodman et al., 1979; Fletcher et al., 
1998), where three analogues are produced: the enantio peptide, where the chirality of all amino acids is 
reversed, the retro-peptide where the amino and carboxy termini are exchanged, and the retro-inverso analogue 
where both modifications are applied at once. Typically, Ret isomers have been used to examine the 
conformation, enzymatic stability and activity of cyclic and linear peptides. In the former case, the Ret isomers 
allowed to lock the absolute three-dimensionnal orientation of the side-chains, independently of the backbone, 
whereas in linear peptides, they have been used to produce four different topochemical arrangements (Goodman 
et al., 1979).  
 
1.4.2.2 Amino acid scans  
 The relative importance of particular functional groups in the primary peptide sequence may be 
determined by conducting various systematic scans and testing for biological activity (Vagner et al., 2008). For 
example, an alanine scan, in which a library of peptides is generated each possessing one amino acid replaced 
by an alanine residue, may determine the importance of the side-chain of each residue for molecular recognition 
and signal transduction contignent on the extent of losses or gains in activity. The importance of stereochemistry 
may be assessed similarly by scanning the sequence with corresponding enantiomeric amino acids. To 
distinguish enantiomeric residues in peptides and proteins, L-amino acids are typically written in capital letters 
whereas their D-counterparts are expressed in lower cases. In L-peptides, introduction of D-amino acids may 
favour turn conformations and destabilize helices, such that the importance of conformation may be inferred. 
Further insight into the stereoelectronic and steric requirements of the receptor binding pocket may be gained by 
modifying the chiral, hydrophobic, steric and acid-base properties of key side-chain moieties. For example, 
tyrosine may be substituted by phenylalanine to address the importance of the phenol H-bond donor capacity as 
well as aromatic electron density. Other scanning approaches, including proline and glycine scans, have 
complementary applications, but will not be discussed here. 
 
1.4.2.3 Local conformational constraints 
 An additional step which may be taken towards identification of the relationships between biological 
activity and conformation entails restricting peptide flexibility to determine which conformers are important for 
activity. This latter corresponds to the conformation adopted by the peptide chain when it binds to its receptor. 
Organization of the peptide chain to bind to its receptor comes with entropic and enthalpic costs, such that 
preorganization by conformational restriction may enhance affinity and potency. Certain secondary structures 
may be energetically preferred (Ramachandran et al., 1968); i.e., helical, extended and turn conformations 
(Figure 1.10). These structures are defined by the backbone dihedral angles phi (ϕ), psi (ψ) and omega (ω), 
respectively about the backbone atoms C'-N-Cα-C', N-Cα-C'-N’, as well as the atoms Cα-C'-N-Cα (Figure 1.11).  
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Figure 1.10. (a) Representative helix, strand and turn secondary structures (PDB ID 3I7W, Lewinski et al., 2009; 
adapted from Lubell et al., 2012) and (b) nomenclature of amino acid positioning in secondary structures: i 
defines the first residue of a fold, whereas i+1 denotes the second residue, and so-on.  
 
Figure 1.11. Dihedral angles of a peptide chain. 
 Nonetheless, elucidation of the bioactive conformation of a peptide may be challenging, due to the 
inherent flexibility of most small linear peptides, but may be facilitated by limiting flexibility through constraint of 
the dihedral angles by cyclization. Cyclizations from side chain to side chain, side chain to backbone, C-terminus 
to N-terminus, backbone to backbone and various combinations have been used to bias the entire or specific 
sections of the peptide to favour particular conformations. Positional scanning by replacement of amino acids 
with cyclic counterparts, such as proline and pipecolic acid (Homoproline, Hpr), cyclic urea derivatives, or 
lactams, places local constraints on the backbone dihedral angles (Figure 1.12) (Maes et al., 2009; Hopewell et 
al., 2012). Alternatively, α-substituted amino acids can be used to bias the backbone conformation towards α-
helix, extended or β-turn conformations, depending on the nature of the α-substitution and the nature of the group 
attached to the first side-chain carbon (χ
1
). For example, sterically hindered dialkyl amino acids such as α-
aminoisobutyric acid (Aib), α,α-diethylglycine (Deg), and 1-aminocycloalkane-1-carboxylic acids (Acnc, with n=3-
8) may favour helices (Figure 1.13) (Grieco et al., 2002; Marshall et al., 1990).  
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Figure 1.12. Cyclic α-amino acids as local conformational constraints. 
 
Figure 1.13. Dialkyl α-amino acids as secondary structures stabilizers. 
 
1.4.2.4  Bicycles as global conformational restrictions  
 Bicyclic templates are commonly used as global rigidifying moieties, because they restrict conformations 
by a combination of structural constraints and steric interactions (Vagner 2008). Azabicycloalkanone amino acids 
are dipeptide surrogates (Hanessian et al., 1997; Halab et al., 1998; Gosselin et al., 2000; Cluzeau et al., 2005) 
containing side chain to side chain and side chain to backbone constraints, which may mimic type II’ β-turn 
geometry contingent on stereochemistry. Many azabicycloalkanone derivatives have been made incorporating 
variations of ring substituent, stereochemistry and size, including [5,5]-pyrrolizidinone, [6,5]-indolizidin-2-one 
(I
2
aa), [6,6]-quino-lizidin-2-one (Q
2
aa), [5,6]-indolizidin-9-one (I
9
aa), [7,5]-pyrroloazepin-2-one (P
2
aa), and [8,5]-
pyrroloazocinone (Figure 1.14; Vagner et al., 2008). 
 
Figure 1.14. Typical azabicycloalkanone amino acids (adapted from Vagner et al., 2008). 
 
1.4.2.5 Side-chain constraints  
 Most amino acid side-chains have relatively unhindered rotations about their torsional angles: referred to 
as χ
1
 for the angle between Cα-Cβ bonds, χ
2 
for the Cβ-Cγ bond, and so on (Figure 1.11). For example, low 
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barriers for rotation exist between the three minimum energy conformations about χ
1
: gauche (–), gauche (+) and 
trans. In contact with the receptor, certain side-chain topography may be important for molecular recognition and 
signal transduction, which can be identified by replacing more flexible amino acids by rigid analogues. For 
example, hydrogen atoms may be replaced by methyl groups to bias side-chain torsional angle geometry and 
hinder rotation, such as with β-methyl-2′,6′-dimethyltyrosine (trimethyltyrosine, TMT), 1-amino-2,2’-
dimethylcyclopropane carboxylic acid (c3Val) and β-methylphenylalanine (MePhe), can be utilized (Hruby et al., 
2000).  Employing such residues to favour distinct χ
1
 side-chain conformations may help elucidate the preferred 
chain topography.  
 
1.4.2.6  Isosteric replacements 
 Protease-resistance may be achieved by replacement of amide bonds with non-hydrolysable isosteres 
(Figure 1.15) (Spatola et al., 1986; Vagner et al., 2008). Amide bond isosteres may also restrict flexibility, alter 
peptide geometry and hydrophilicity through distinct hydrogen bonding patterns and inter-residue length.   
 
Figure 1.15.  Common amide bond isosteres (Vagner et al., 2008). 
 
1.4.2.7  Other substitutions 
 Other key strategies used in peptide mimicry feature modifications of the amino acid backbone carbon 
(Cα). For example, aza-amino acids (carbazic acids) may stabilize secondary structures by adding stereo-
electronic restrictions about the Nα (Proulx et al., 2011). Similarly, peptides bearing β- or γ-amino acids, as well 
as N-alkyl glycines (peptoids), all have been used to alter the conformation and pharmacokinetic properties of 
peptides (Krauthäuser et al., 1997). In addition, chemical end capping by N-acylation, C-esterification and C-
amidation, glycosylation, pegylation and N-alkylation, have been utilized in varying ways to modify conformation 
and to enhance plasma stability, reduce immunogenicity and retard excretion through the kidneys (Chalmers et 
al., 1995).  
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1.4.3 Challenges in peptide mimicry 
 In spite of success, peptide mimicry remains a challenging task, because of the difficulties in accurately 
mimicking larger sections of protein secondary and tertiary motifs (e.g. β-sheets) using smaller synthetic 
surrogates, synthetic challenges and limited guidelines for translating relatively flexible sequences into mimics of 
particular active conformations. Combination of multiple chemical strategies has thus been essential for 
optimizing a peptide lead into a more viable drug candidate. 
 
1.5 Previous work 
1.5.1 Discovery of 101.10 
 On the basis of the overall rationale presented above, a library of interface peptides was generated from 
sequences of the flexible portions of the IL-1RAcP, which were known to interact with IL-1RI (Chemtob et al., 
2005; Quiniou et al., 2008). Subsequent pharmacological testing, truncation and examination of the enantiomeric 
sequence resulted in the discovery of a selective D-peptide antagonist of IL-1RI, termed 101.10 (rytvela), which 
exhibited key features of an allosteric modulator and efficacy in models of acute bouts of inflammation. 
 In this process, the extracellular loops and interdomain regions of the IL-1RAcP were identified based on 
the crystal structure and modeling data of the cytosolic portions of the IL-1RI/IL-1β/IL-1RAcP complex. The 
hydrophobic domains and flexibility profiles of the loops, as well as their homology with other proteins domains 
were analyzed using various softwares (PROSITE, ProtScale and ProDom) to provide an initial library of fifteen 
all D-configured, sense or anti-sense peptides (Figure 1.16). These peptides were tested for potential to modulate 
IL-1β-stimulated PGE2 formation. Among the candidates, a peptide (101, aprytvela) from the juxtamembranal 
flexible loop of the accessory protein exhibited promising activity.  
 Successive D-alanine and N-terminal truncation scans were conducted, and resulting analogues were 
examined for their activity against IL-1β-triggered proliferation of endothelial cells and phosphorylation of 
downstream effectors p38 MAPK and IκB (Chemtob et al., 2005). The D-heptapeptide 101.10, (rytvela, D-Arg
1
-D-
Tyr
2
-D-Thr
3
-D-Val
4
-D-Glu
5
-D-Leu
6
-D-Ala
7
) (Figure 1.17) shown efficacy and potency in a broad variety of in vitro IL-
1β-dependent assays: proliferation of thymocytes (IC50 = 0.2 nM) and human lung fibroblasts (IC50 = 2 nM; Emax ≥ 
90%), as well as PGE2 synthesis (IC50 = 0.5 nM; Emax ≈ 50%) (Quiniou et al., 2008). Radiolabelled ligand binding 
experiments revealed the noncompetitive nature of 101.10 on inhibition of IL-1β action and on modulation of IL-
1β-binding affinity. The effects of 101.10 were selective for IL-1β and did not affect the activity of homologous 
cytokines of the IL-1 family: no changes in IL-18-iduced TNF-α- and LPS-dependent JNK as well as p38 
phosphorylation, nor IL-6-induced Erk1/2 phosphorylation were observed using 101.10. The in vivo efficacy of 
101.10 was evaluated in animal models of inflammatory conditions and proved superior to corticosteroids and 
anakinra. In models of hyperthermia, hypotension, trinitrobenzene sulfonic acid (TNBS)-induced inflammatory 
bowel disease and phorbol myristate acetate (PMA)-triggered contact dermatitis, 101.10 demonstrated robust 
anti-inflammatory effects. Morevoer, 101.10 failed to bind to IL-1RI-deficient cells and was ineffective in vivo in IL-
1RI-knockout mice (Quiniou et al., 2008).  
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Figure 1.16. Ribbon-like model of IL-1RI/IL-1β/IL-1RAcP complex (a) and primary sequence of the extracellular 
portion of IL-1RAcP (b). Colored sequences refer to regions that were used to derive interface peptides (Quiniou 
et al., 2008).  
 
Figure 1.17. Structure of the lead D-heptapeptide 101.10. 
 In summary, 101.10 exhibited potent, selective, and reversible non-competitive inhibition of IL-1β 
activity, without interacting with the ligand binding site, albeit by affecting IL-1β-binding affinity and by interfering 
variably with different in vitro responses to IL-1β. These features distinguished 101.10 as a modulatory 
Chapter 1 21 
 
antagonist distinct from the FDA-approved competitive inhibitor anakinra, and the sequestering molecules 
rilonacept and canakinumab. To improve 101.10 as a drug candidate, efforts were initiated, as described below. 
 
1.5.2  Optimization of 101.10  
 Modifications were performed on 101.10 to identify the key pharmacophore elements necessary for 
binding to IL-1RI and to elicit activity (Chemtob et al., 2005). In attempts to decipher the relative importance of 
functional groups, systematic conservative replacements of amino acids with analogous residues were conducted 
at each position along the sequence: i.e., Arg
1
 for Cit, Orn and Lys; Tyr
2
 for Phe and Trp; Thr
3
 for Val and Ser; 
Val
4
 for Pro; Glu
5
 for Asp and Gln; Leu
6
 for Ile, Met, Val and Ala. Although rytpela exhibited good potency, it was 
discarded due to low aqueous solubility and poor in vivo properties. Successive N-terminal truncations identified 
the region minimum sequence for eliciting antagonistic activity to be Thr
3
-Val
4
-Glu
5
-Leu
6
 (Chemtob et al., 2005).  
 
1.5.3 Project objectives 
 In light of the earlier findings, the lead peptide 101.10 has been examined further to identify regions of 
secondary structure necessary for recognition by IL-1RI and activity against IL-1β. Approximately 100 new 
peptides, peptidomimetics and small analogues of 101.10 have been generated, characterized and tested for 
biological activity. This master thesis relates specifically my contribution in this effort, and presents current 
hypotheses concerning the mode of of action of this peptide as well as promising mimics.  
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2.1  Introduction 
 Amino-γ-lactams have been utilized to restrict the mobility, increase selectivity and enhance potency of 
peptides. Insertion of such lactam residues into a linear peptide may confine the degrees of freedom about the ω 
and ϕ dihedral angles and diminish the number of rotatable bonds (Freidinger et al., 1980; Liskamp, 1994; 
Loughlin et al., 2010). Among different types of amino-γ-lactams described, two have been mainly used in 
peptide science : α-amino-γ-lactam (Agl) and β-amino-γ-lactam (Bgl) (Figure 2.1).  
 
Figure 2.1. Structure of α- and β-amino-γ-lactams (Agl and Bgl, respectively). 
 
Figure 2.2. Structure of LH-RH and a (S)-Agl
6
 analogue.  
 α-Amino-γ-lactam was first introduced in luteinizing hormone-releasing hormone (LH-RH; 2.1) by 
Freidinger and co-workers, producing an analogue (2.2) with 8.9 times greater potency than the parent peptide in 
a pituitary cell culture assay, and exhibited evidence of a bioactive β-turn conformation (Figure 2.2; Freidinger et 
al., 1980b). An Agl-containing peptidomimetic (2.3) has also demonstrated potent and selective inhibition (Ki = 7 
nM) of blood coagulation factor Xa (FXa) in both the rat model of FeCl2-induced carotid artery thrombosis and the 
rabbit model of jugular vein thrombus formation (Ewing et al., 1999). The crystal structure of the 
aminoisoquinoline pyrrolidinonesulfonamide inhibitor named RPR208815 (2.3) bound to the human FXa (Figure 
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2.3) shows the geometrical restrictions produced by the central amino-γ-lactam, necessary to occupy and block 
the enzyme S1 and S4 pockets (Maignan et al., 2000). 
 
Figure 2.3. Crystal structure of blood coagulation factor Xa complexed with an Agl-bearing inhibitor named 
RPR208815 (PDB ID 1F0R, Maignan et al., 2000). 
 Relative to its α-amino equivalent, β-amino-γ-lactam has been less frequently employed to examine the 
active conformation of peptides. One notable investigation involves the introduction of a Bgl moiety into the 
minimum peptidic sequence exerting the hypoglycaemic activity of the human growth hormone (hGH), the 
fragment [6-13]-hGH. Replacement of Asp
11
 for (S)-Bgl produced an analogue favouring a type II’ β-turn (Lee et 
al., 1997) which exhibited extended half-life and preserved biological activity (Ede et al., 1990; Ede et al., 1991; 
Ede et al., 1994). 
 Agl and Bgl substitutions may be utilized conjointly to take advantage of the distinct orientations of the 
carbonyl in each lactam ring to study conformational effects. For instance, Agl and Bgl have been respectively 
incorporated into L-prolyl-L-leucyl-glycinamide (PLG), a short peptide modulator of the D2 dopamine receptors 
within the central nervous system. These two PLG mimics displayed pharmacological profiles that resembled the 
parent tripeptide with 100 to 1000 greater potency (Dolbeare et al., 2003). In addition, amino-γ-lactams have 
been components of strong chemotherapeutic and antibiotic agents, displaying nanomolar inhibition of serine and 
cysteine proteases (Scheidt et al., 1998; Marquis, 2000; Powers et al., 2002; Freidinger, 2003). In these studies, 
the lactams were hypothesized to act as transition state mimics and both the direction of the carbonyl and the 
stereochemistry of the amino group affected the ability to inhibit the enzymes tested (Marquis, 2000; Freidinger, 
2003). Systematic lactam scanning with both Agl and Bgl may therefore represent an effective tool for studying 
conformation and for building complementary mimics of active peptide-based drugs. 
 
2.2  Synthesis of amino-γ-lactams 
2.2.1 Previous synthetic approaches 
 Several strategies have been developed for the insertion of Agl into peptide sequences (Freidinger et 
al., 1980b; Wolf et al., 1989; Schuster et al., 1997; Wolfe et al., 1997; Piscopio et al., 1998; Armstrong, 1998; 
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Piscopio et al., 1999; Freidinger, 2003; Scott et al., 2004; Lama et al., 2005; Galaud et al., 2005; Bhooma et al., 
2006; Raghavan et al., 2006; Nöth et al., 2008). The production of libraries of analogues has however been 
limited, because the synthesis of the dipeptide lactam has been typically performed in solution before 
incorporation into the peptide by solid-phase synthesis (Freidinger, 2003; Scott et al., 2004). Few solid-phase 
strategies for lactam synthesis had been elaborated, and most were restricted to the synthesis of dipeptides 
bearing terminal five- and six-membered rings (Scott et al., 2004; Lama et al., 2005), with limited stereocontrol 
and unsatisfactory yields, precluding any combinatorial usage. In addition, various solution-phase methods have 
been described to synthesize Bgl-containing peptides (Ede et al., 1990; Ede et al., 1991; Ede et al., 1991b; 
Boyarskaya et al., 2005; Dolbeare et al., 2003): however, to the best of our knowledge, no solid-supported 
methodologies have been reported prior to our work (Jamieson et al., 2009).  
 
2.2.2 Our synthetic methodology  
 In the pursuit of an optimized lead from 101.10, twenty peptidomimetics (2.8-2.27; Table 2.1 and 2.2) 
bearing respectively an Agl or Bgl residue of either (R)- and (S)-configuration were synthesized using two 
different solid-phase Fmoc-compatible methods. In the Agl and Bgl cases (Scheme 2.1 and 2.2), the approach 
featured regiospecific N-alkylation and lactam annulation onto peptides supported on resin beads employing 
respectively enantiomerically pure six- and five-membered cyclic sulfamidates (2.5 and 2.7) derived from 
homoserine (2.4) and aspartic acid (2.6), as chiral educts (Jamieson et al., 2009; Boutard et al., 2011). 
Subsequently, insertion of single and multiple Agl residues into the same peptide was achieved via an analogous 
method which employed SynPhase® lanterns as solid support (Ronga et al., 2010).  
 
Scheme 2.1. Rink amide resin synthetic approach for Agl-scanning in peptides. 
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Scheme 2.2. Rink amide resin synthetic approach for Bgl-scanning in peptides. 
 Employing the resin bead method described above, the Agl analogue 2.8 was resynthesized in the 
course of this thesis, with improvement on some aspects of the strategy. Specifically, the use of phase-transfer 
catalysis for the benzylation of L-homoserine and alkylation of the N-terminal unprotected peptide without 
additional bis-alkylation, simplified the synthetic protocols and improved conversions and yields. The lactam 
peptide 2.8 was recovered in high crude purity and isolated yield, as assessed by analytical RP-HPLC (Table 
2.1). 
Entry Peptide 
Crude 
purity 
%
a
 
Purity 
%
a
 
Yield 
%
b
 
HRMS
c
 
m/z  
(calcd) 
m/z  
(obsd) 
2.8 D-Arg-D-Tyr-(R)-Agl-D-Val-D-Glu-D-Leu-D-Ala-NH2 94 > 99 8.4 832.4675 832.4665 
Table 2.1. Yields and purities of lactam-containing analogue 2.1 of 101.10. 
a
 RP-HPLC purity at 280 nm. 
b
 Yields 
after purification by RP-HPLC are based on Fmoc loading test for Rink resin. 
c
 HRMS values from the major 
protonated molecule, typically [M+H]
+
. 
 
2.3  Structure-activity relationships of amino-γ-lactams 
2.3.1 Conformational analysis 
 Conformational changes of macromolecules may be assessed using circular dichroism. For example, 
folding and unfolding of biomolecules (proteins, nucleic acids, and glycosides) may be monitored as changes in 
circular dichroism (CD) spectra features such as the curve shape and the intensity of positive and negative 
maxima. Algorithms such as the Chou-Fasman-Prevelige have been used as protein secondary structures 
prediction software (Prevelige et al., 1989). Signal in the far-UV region (< 250 nm) may be attributed to peptide 
amide bonds adopting different types of secondary structures. For instance, a negative n  π* transition band at 
195 nm combined with a positive π  π* transition band near 212 nm has been indicative of a disordered 
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peptide structure, so-called "random coil" (Kelly et al., 2005). Noteworthy, secondary structures composed of L-
amino acids give rise to CD curves that are mirror images of their D-amino acid counterparts.  
Entry Peptide 
2.9 (R)-Agl-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.10 D-Arg-(R)-Agl-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.11 D-Arg-D-Tyr-D-Thr-(R)-Agl-D-Glu-D-Leu-D-Ala-NH2 
2.12 D-Arg-D-Tyr-D-Thr-D-Val-(R)-Agl-D-Leu-D-Ala-NH2 
2.13 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-(R)-Agl-D-Ala-NH2 
2.14 D-Arg-D-Tyr-(S)-Agl-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.15 D-Arg-D-Tyr-D-Thr-(S)-Agl-D-Glu-D-Leu-D-Ala-NH2 
2.16 (R)-Bgl-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.17 D-Arg-(R)-Bgl-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.18 D-Arg-D-Tyr-(R)-Bgl-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.19 D-Arg-D-Tyr-D-Thr-(R)-Bgl-D-Glu-D-Leu-D-Ala-NH2 
2.20 D-Arg-D-Tyr-D-Thr-D-Val-(R)-Bgl-D-Leu-D-Ala-NH2 
2.21 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-(R)-Bgl-D-Ala-NH2 
2.22 (S)-Bgl-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.23 D-Arg-(S)-Bgl-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.24 D-Arg-D-Tyr-(S)-Bgl-D-Val-D-Glu-D-Leu-D-Ala-NH2 
2.25 D-Arg-D-Tyr-D-Thr-(S)-Bgl-D-Glu-D-Leu-D-Ala-NH2 
2.26 D-Arg-D-Tyr-D-Thr-D-Val-(S)-Bgl-D-Leu-D-Ala-NH2 
2.27 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-(S)-Bgl-D-Ala-NH2 
Table 2.2. Agl- and Bgl-bearing analogues synthesized by Dr. Andrew G. Jamieson, Dr. Luisa M. Ronga, Dr. 
Nicolas Boutard and Stéphane Turcotte. 
 Accordingly, conformational effects of the amino-γ-lactams on peptides were assessed by far-UV-CD 
spectroscopy in water, performed between 190 and 260 nm. For comparison between different analogues, all CD 
data were background-substracted and then normalized to mean residue ellipticity, [θ], reported in units of 
mdeg∙cm
2
∙dmol
-1
∙residue
-1
. The [θ] values were calculated from θ data directly obtained from the CD instrument, 
according to equation 2.1 (Whitford, 2005): 
[θ] = MRW∙θ/10∙d∙c 
Equation 2.1. Conversion of degree of ellipticity to mean residue ellipticity, where [θ] is mean residue ellipticity 
(mdeg∙cm
2
∙dmol
-1
∙residue
-1
), MRW corresponds to mean residue weight (molecular weight divided by the number 
of residues; g∙dmol
-1
∙residue
-1
), θ is degree of ellipticity (mdeg), d relates to the cell pathlength (cm), and c is the 
sample concentration (g∙cm
-3
). 
Chapter 2 32 
 
 CD curves were then interpreted based on established correlations of maxima band values and curve 
shapes (Figure 2.4; Kelly et al., 2005; Whitford, 2005; Shemer, 2009) with typical secondary structures. For 
example, the CD spectra of lead peptide 101.10 was compared with selected Agl and Bgl analogues (Figure 2.5). 
 
Figure 2.4. Representative far-UV CD a) curves and b) transition bands associated with various types of 
secondary structure. Solid line, α-helix; upside triangles, antiparallel β-sheet; downside triangles, type I β-turn; 
and circles, random coil (graph reproduced from Woody, 2010; table values taken from Hutchinson et al., 1994; 
Ranjbar et al., 2009; Moradi et al., 2009).  
 The CD curve for the parent peptide (5.1; see chapter 5) indicated a disordered structure, as suggested 
by the positive maxima around 198 nm and the negative shoulder in the longer wavelength. The insertion of a 
lactam motif into the rytvela core had a pronounced influence on the shape of the CD spectra, contingent on 
location, stereochemistry and Agl versus Bgl structure. The spectra of analogues bearing an (R)-Agl, (R)- or (S)-
Bgl at the third position (2.8, 2.18 and 2.24) were suggestive of a type II’ β-turn, displaying one negative and two 
positive bands near 205 ,195 and 225 nm, respectively. The CD shapes of (R)-Agl analogues at the valine, 
glutamate and leucine positions (data not shown) showed two distinct maxima at 200 and 220 nm, indicating a 
prevalent type I β-turn fold. Alternatively, the (S)-Agl
3
 analogue (2.14) exhibited a curve shape ressembling that 
of a random structure, whereas the (S)-Agl
4 
analogue (2.15) produced a spectrum suggesting very discrete 
amounts of β-turn. The CD curves of the C-terminal (R)-Bgl analogues at positions 4, 5 and 6 (data not shown) 
exhibited positive maxima at 195 nm, suggesting a random coil. (S)-Bgl analogues induced stronger changes in 
ellipticity and respectively on peptide conformation than their (R)-counterparts. In brief, this ensemble of CD data 
demonstrated that introduction of Agl or Bgl residues may infer a broad spectrum of secondary structures into 
101.10. Ideally, such induced structures may be correlated to good anti-IL-1β biological activty, as described 
next. 
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 Figure 2.5. CD of 101.10, and a) selected Agl analogues, as well as b) Bgl analogues. 
 
2.3.2 Biological activity 
 The biological activity of the lactam analogues was ascertained by measuring their influence on IL-1β-
induced human thymocyte (TF-1 cell line) proliferation, as assessed by two methods. The first method consisted 
in the incorporation of [
3
H]-thymidine into DNA of mitotic cells, and was used to test Agl-bearing peptides (2.8-
2.15; Figure 2.6a). Nonetheless, several inconveniences such as the expensive disposal of radioactive wastes, 
the poor radionucleus’ quantum yield, the labour-intensiveness of the procedure and the relatively low accuracy 
limited this method. A second assay was thus developed, featuring the intercalation of a cyanine dye (termed 
CyQUANT NF) into the nuclear and mitochondrial DNA of cells, which generates a 100-fold raise in fluorescence 
intensity. This second method presented notable advantages, including suitability for high-throughput screening 
(HTS), greater affordability, a wider dynamic range and higher sensitivity. After optimization and validation with 
previously obtained data, this later method was subsequently used to test the Bgl analogues (2.16-2.27; Figure 
2.6b). The biological data are reported herein as percentage of control (non-stimulated) proliferation.  
 In both assays, the lead peptide showed a maximum efficacy of 100%, completely abrogating 
exogenous IL-1β-induced thymocyte proliferation. Among all analogues, seven maintained inhibitory effects on 
TF-1 proliferation (2.9-2.13, 2.25 and 2.26), of which five showed a 1.3- to 2.2-fold increase in efficacy compared 
to 101.10. Introduction of (R)-Agl in rytvela caused, in all positions except the third one (analogue 2.8), an 
amplification or retention of the activity. Notably, replacement of the N-terminal D-Arg
1
 residue by (R)-Agl (2.9) led 
to the most effective peptidomimetic in the series, causing a 2.2-fold increase in efficacy compared with the 
parent peptide. In the case of (S)-Bgl, only substitutions at positions 4 and 5 (2.25 and 2.26) maintained activity. 
In particular, replacing D-Val
4
 for (S)-Bgl (2.25) produced the most potent of the Bgl library, bearing a 1.3-fold 
increase in activity. Both (S)-Agl (2.14 and 2.15) as well as four (R)-Bgl derivatives (2.16, 2.17, 2.19 and 2.21) 
exacerberated the immune cell proliferation. 
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Figure 2.6. Inhibition of IL-1β-induced thymocyte proliferation by a) Agl and b) Bgl analogues. Vehicle column 
represents cells that were not treated with a peptide, and all columns correspond to cells that were stimulated by 
an exogenous amount of hIL-1β. The numbers correspond to the entry number of the analogue and the color to 
the stereochemistry of the lactam. Samples that display more than 100% inhibition of IL-1β-mediated effect are 
suspected to block the endogenous production of IL-1β in cells as well.  
 Overall, it seems that the stereochemistry, the position in the sequence and the orientation of the 
carbonyl of the lactam have a significant influence on the activity of the peptide. For instance, the derivatives 
containing (R)-Agl
4
 or (S)-Bgl
4
 (2.11 and 2.25), which share comparable carbonyl orientations and amino group 
positions, formed the two most active lactam series. Swapping (S)-Bgl for (R)-Bgl shows little impact on the first 
three positions, whereas the effect is more drastic on positions 4 to 6. Typically, substitution of D-Thr
3
 for a lactam 
(2.8, 2.14 and 2.18) induced a significant loss of anti-IL-1β efficacy, which may be in part attributed to the loss of 
the hydroxyl group side-chain.  
 
Figure 2.7. Structure-activity relationships observed via amino-γ-lactam scanning of 101.10. 
 
2.4  Concluding remarks 
 In light of the CD spectra and biological data, some persistent structure-activity relationships were 
observed (Figure 2.7.). For example, introduction of (R)-Agl in the peptide induced higher anti-IL-1β efficacy and 
stronger turn motifs than most of the Bgl and all of the (S)-Agl counterparts. Nonetheless, in the Bgl group, the 
(S)-stereochemistry produced the strongest turn motifs as well as three active analogues. These findings suggest 
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that the carbonyl and amino group orientation as well as the stereochemistry of the lactam are critical. 
Replacement of the D-Thr
3
 by a lactam caused, in 75% of cases, a β-turn fold associated with a substantial loss 
in activity. However, this reduction of biological effect may be attributed to the absence of the hydroxyethyl side-
chain rather than the rigidification of conformation. This hypothesis will be tested in a subsequent series of 3
rd
 
position analogues, the α-amino-β-hydroxy-γ-lactam (Hgl), presented in chapter 3. These results suggest again 
that a fold induced in the central portion of the peptide may be important for activity, but not at the detriment of 
side-chain loss. Agl and Bgl scanning of 101.10 have thus proven useful and complementary for enhancing 
peptide potency and identifying conformational requirements for biological activity. 
 
2.5  Experimental section 
2.5.1 General 
 Unless otherwise specified, starting materials and reagents were obtained from commercial sources and 
used as received. Rink amide MBHA (100-200 mesh) resin was purchased from Novabiochem (EMD Bioscience, 
California, USA). L-Homoserine was purchased from Novabiochem (EMD Bioscience, California, USA). Fmoc-
amino acids were purchased from Novabiochem (EMD Bioscience, California, USA) or GL Biochem (Shangai, 
China). O-Benzotriazole-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) was purchased from GL 
Biochem (Shangai, China). Anhydrous solvents (THF, MeCN, DCM and DMF) were obtained from a Seca 
Solvent Filtration System (GlassContour, Laguna Beach, USA). Triethylamine (TEA) and diisopropylethylamine 
(DIEA) were purchased from Sigma-Aldrich (Missouri, USA) and distilled from calcium hydride. For reactions 
requiring anhydrous conditions, glassware, syringes and needles were flame dried immediately prior to use and 
allowed to cool either in a desiccator or under an atmosphere of dry argon; liquids were added via syringe or 
cannulation through rubber septa in a system maintained under an atmosphere of argon. The removal of solvents 
in vacuo was achieved using a Büchi rotary evaporator at a pressure of 15 mm Hg, generated by a water 
aspirator.  
 
2.5.2 Characterization and purification 
 Flash column chromatography was carried out using SiliaFlash F60 silica (Silicycle, Québec, CA). 
Precoated glass-backed plates (SiliaPlate S8 TLC Extra Hard Layer F-254, Silicycle, Québec, CA) were used for 
thin layer chromatography (TLC) and were visualized by either UV fluorescence or staining with molecular iodine, 
ninhydrin, phosphomolybdic acid (PMA) or KMnO4 solution followed by heating. 
 Analytical high-performance liquid chromatography (HPLC) and mass spectral (MS) data were obtained 
using the capLC-MSD Quad (Agilent Technologies) from the Mass Spectrometry Facility of Université de 
Montréal (Québec, CA), equipped with the electrospray ionization (ESI) and a single quadrupole. Likewise, high 
resolution mass spectrometry (HRMS) data were recorded with a LC-MSD Time-of-Flight (TOF) (Agilent 
Technologies, Santa Clara, USA) instrument at the same instrumental facility. Analytical reverse phase (RP)-
HPLC analyses were performed on either a Gemini® C18 (5µm, 110Å, 150 mm x 4.60 mm I.D.; Phenomenex, 
Torrance, USA) or a Synergi® RP-Polar column (4µm, 80Å, 150 mm x 4.60 mm I.D.; Phenomenex, Torrance, 
USA) with a flow rate of 0.5 mL/min. Unless otherwise specified, linear gradients of acetonitrile or methanol in 
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water (all HPLC grade solvents), modified with either 0.1% formic acid (FA) or trifluoroacetic acid (TFA), were 
used. Peptides and analogues were purified via preparative RP-HPLC using a Gemini® C18 (5µm, 110Å, 250 
mm x 21.2 mm I.D.; Phenomenex, Torrance, USA) or a Synergi® RP-Polar column (4µm, 80Å, 150 mm x 21.2 
mm I.D.; Phenomenex, Torrance, USA) submitted to a specified linear gradient, at a flow rate of 10.6 mL/min. 
Retention times (tR) from RP-HPLC are reported in minutes. 
 
2.5.3 Microwave chemistry 
 Microwave-assisted reactions were preformed in a Biotage Initiator Sixty or Eight microwave apparatus 
(Biotage AB, Uppsala, SE) with samples prepared in 0.5-2.0mL glass reaction vessels containing a triangular 
magnetic stirrer bar and sealed with an aluminum-bordered septum cap. 
 
2.5.4 Synthesis of peptides and mimetics by standard Fmoc-SPPS 
2.5.4.1 Rink resin swelling and deprotection 
 Rink amide MBHA resin (300 mg, 0.21 mmol, 0.7 mmol/g) and DMF (7 mL) were charged in a 12 mL 
plastic filtration tube fitted with a polyethylene filter. The tube was sealed and shaken for 30 min. at room 
temperature (r.t.). The resin was filtered and taken up in freshly prepared 20% piperidine in DMF solution (7 mL), 
shaken for 30 min. and filtered. The resin was retreated with 20% piperidine/DMF solution (7 mL) and shaken for 
another 30 min. The resin was washed by consecutive 1 min. agitations and filtered from DMF (3 x 7 mL), MeOH 
(3 x 7 mL) and DCM (3 x 7 mL). A positive Kaiser colour test indicated qualitatively the presence of free amine 
(Kaiser 1970). 
 
2.5.4.2 Amino acid coupling 
 The resin was first swollen in DMF (7 mL) for 15 min. In a separate 20 mL-glass vial, a solution of N-
(Fmoc)amino acid (Fmoc-Xaa-OH, 3 equiv.), HBTU (3 equiv.) and DIEA (6 equiv.) in DMF (7 mL) was stirred for 
10 min. and then added to the resin. The resin mixture was shaken for 1 h with Fmoc-D-Ala-OH, 3 h with Fmoc-D-
Val-OH, and 4 h with Fmoc-D-Leu-OH, Fmoc-D-Glu(tBu)-OH, Fmoc-D-Thr(tBu)-OH, Fmoc-D-Tyr(tBu)-OH and 
Fmoc-D-Arg(Pbf)-OH, at room temperature. The resin was filtered and respectively washed by shaking for 1 min. 
with DMF (3 x 7 mL), MeOH (3 x 7 mL) and DCM (3 x 7 mL). A negative Kaiser colour test result indicated 
completion of the reaction.  
 
2.5.4.3 Resin capping 
 In cases in which a coupling did not proceed to completion, the resin was swollen in a solution of acetic 
anhydride (Ac2O, 10 equiv.) in DMF (7 mL), treated with DIEA (10 equiv.), shaken for 2 h, filtered, washed by 
shaking for 1 min. with DMF (3 x 7 mL), MeOH (3 x 7 mL) and DCM (3 x 7 mL) and dried in vacuo. 
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2.5.4.4 Chain alkylation 
 After swelling the resin, the Fmoc protecting group was removed as described above. For the installation 
of Agl, the resin was treated by vigorous shaking with a solution of 6-membered sulfamidate (5 equiv.) in THF (7 
mL) for 24 h, filtered, washed with THF (3 x 7 mL), MeOH (3 x 7 mL) and DCM (3 x 7 mL) and dried in vacuo 
(Jamieson et al., 2009). In the case of Bgl, the resin-bound peptide was alkylated by addition of a solution of 5-
membered sulfamidate (5 equiv.) in THF (2 mL), after which DIEA (1 equiv.) was added, and heated at 60ºC 
using microwave irradiation for 1.5 h (Boutard et al., 2011).  
 
2.5.4.5 Microwave-assisted annulation 
 The resin was transferred into a 0.5-2 mL glass microwave vial, and treated with a freshly prepared 1% 
AcOH/DMSO solution (2 mL). The vial was sealed, heated in the microwave at 100 ºC (pressure 1 bar) for 3 h, 
cooled using a jet of air, washed  from the microwave vessel into a 12 mL plastic filtration tube with polyethylene 
frit, rinsed by shaking for 1 min. using DMF (3 x 7 mL), MeOH (3 x 7 mL) and DCM (3 x 7 mL) and dried in vacuo.  
 
2.5.4.6  Peptide cleavage 
 As described above, the resin was swollen in DMF and the Fmoc group was removed. A positive Kaiser 
test demonstrated qualitatively the presence of free amine. The resin was shaken in TFA/H2O/triethylsilane (TES) 
(7 mL, 95/2.5/2.5, v/v/v) for 2 h at room temperature, filtered, washed with TFA (7 mL) and the combined filtrate 
and washings were concentrated in vacuo up to a volume of 1 mL. The resulting residue was transferred to a 50 
mL Falcon centrifuge tube and precipitated by the addition of ice-cold diethyl ether (Et2O, 40 mL). The mixture 
containing the precipitate was centrifuged and the diethyl ether was carefully decanted from the tube. The 
precipitated peptide was washed with cold Et2O, centrifuged and decanted once more. The resulting white 
amorphous solid was dissolved in water (10 mL) and freeze-dried to give a white fluffy solid that was analyzed for 
purity and isolated using the previously specified conditions. 
 
2.5.5 Ultraviolet-circular dichroism 
 Determination of the aqueous concentration of peptides was performed by UV-quantification using Beer-
Lambert law (Equation 2.2; IUPAC, 1997) : 
A = ε∙c∙l 
Equation 2.2. Beer-Lambert law, where A relates to the absorbance (a.u.), ε corresponds to the molar absorption 
coefficient (L∙mol
-1
∙cm
-1
), c is the concentration (mol∙L
-1
) and l the cuvette pathlength (cm). 
 
 UV absorbances of aqueous peptide solutions were recorded on a Varian Cary® 300 UV/Vis 
Spectrophotometer (Varian, California, USA) equipped with a deuterium arc source. Essentially, a spatula tip of 
the purified peptide is dissolved in 1000 µL of Chromspec-filtered Milli-Q water and transferred to a 1.0 cm 
spectrophotometric cuvette. The sample absorbance is measured six times at 280 nm, averaged and subtracted 
from the background signal. The concentration of the solution was calculated using Beer-Lambert law, using the 
molar absorption coefficient of tyrosine at 280 nm (εTyr = 1280 L∙mol
-1
∙cm
-1
). 
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 Far-UV-CD spectra of peptides and peptidomimetics were recorded from 190 to 260 nm on a Chirascan 
CD Spectrometer (Applied Photophysics Ltd., Surrey, UK) using a 1.0-cm pathlength quartz cuvette filled with 20 
µM (unless otherwise specified) of compound dissolved in Chromspec-filtered Milli-Q water. All CD curves were 
subtracted from background signal previously recorded for filtered Milli-Q water. Instrumental settings were fixed 
as the following: bandwidth of 1 nm, step size of 0.5 nm, sampling time of 2 s. Data are expressed in terms of 
mean residue ellipticity, [θ] (mdeg∙cm
2
∙dmol
-1
∙residue
-1
). 
 
2.5.6  Biological activity screening of analogues  
2.5.6.1 [
3
H]-Thymidine incorporation assays  
 IL-1β-induced proliferation of immune cells was assessed by incorporation of [
3
H]-thymidine, as 
previously described (Quiniou et al., 2008). Basically, human TF-1 cells (CRL-2003, American Type Culture 
Collection (ATCC), Virginia, USA) were cultured in complete RPMI medium (Wisent, Québec, CA) supplemented 
with human GM-CSF (2 ng/mL; PeproTech, New Jersey, USA). Cells were splitted (5x10
4
 cells in 200 µL/well) in 
a 96-well culture plate (Corning, New York, USA) and deprived of growth factors for 18 h before preincubation 
with peptide (1 µM) followed by treatment with human IL-1β (10 or 25 ng/mL; PeproTech, New Jersey, USA). 
After 24 h of incubation, [
3
H]-thymidine (1 μCi/mL; Amersham, Amersham, UK) was added and the cells were 
incubated for another 24 h. Cells were harvested, washed twice with PBS (10 mM Na2HPO4, 2 mM KH2PO4, 137 
mM NaCl, 2.7 mM KCl; pH 7.4), and lysed with a 0.1 N NaOH/0.1% Triton X-100 solution. A scintillation cocktail 
(8 mL/sample; Fisher Scientific, Ontario, CA) was added to the lysate, and after 3 h, radioactivity was measured 
with a β-ray counter (Beckman Multi-Purpose Scintillation Coulter Counter LS6500; Beckman Coulter, California, 
USA). Triplicate results were analyzed by one-way analysis of variance (ANOVA) factoring for treatments. Data 
are presented as mean ± standard error of the mean (SEM). 
 
2.5.6.2  CyQUANT NF intercalation assay 
 Immune cell proliferation was assessed by DNA intercalation of CyQUANT NF fluorescent dye (Boutard 
et al., 2011). Essentially, human TF-1 cells (CRL-2003, American Type Culture Collection, Virginia, USA) were 
cultured in complete RPMI 1640 (Gibco-Invitrogen, California, USA) supplemented with human GM-CSF (2 
ng/ml, PeproTech, New Jersey, USA). Cells (passage 5 and at least 85% viable, as verified by trypan blue dying) 
were reincorporated into RPMI 1640 medium deprived of phenol red (Gibco-Invitrogen, California, USA) and of 
growth factors [i.e. fetal bovine serum (FBS) and GM-CSF] for 18 h and split (5x10
3
 cells in 200µL/well) into a 96-
well non-adherent flat bottom culture plate (Sarstedt, Nümbrecht, Germany). Following 15 min. preincubation with 
peptide (1 μM), the cells were treated with human IL-1β (25 ng/mL, PeproTech, New Jersey, USA) and 
reincubated. After 48 h, the cells were centrifuged for 7 min. at 300 g, reincorporated into Hank’s Buffered Salt 
Solution (1X HBSS, 50 μL/well; Invitrogen, California, USA) and transferred into a 96-well polystyrene black plate 
(Corning, New York, USA). An additional 50 µL of a solution made with CyQUANT NF dye (1X component A; 
Invitrogen, California, USA) and CyQUANT NF delivery agent (1X component B; Invitrogen, California, USA) in 
1X HBSS were added to the cells in each well, which were covered with aluminum foil and incubated for 45 min. 
at 37°C. Fluorescence intensity was measured using a microplate reader (Perkin Elmer Wallac Envision 2104; 
Perkin Elmer, California, USA) with excitation at 485 nm and emission detection at 530 nm (using FITC 485 and 
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FITC 535 filters, respectively). Hexaplicate experiments were repeated three times and results were analyzed by 
one-way analysis of variance (ANOVA) factoring for treatments, and data are presented as mean ± standard 
error of the mean (SEM). 
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3.1 Introduction 
 Nature is typically composed of molecules possessing only one of two possible mirror images (Wallace, 
2010). A corollary of such natural enantio-selection is that the form and function of biologically active peptides is 
governed by their chirality (Lubell et al., 2012). Although L-amino acids are predominant, natural entities such as 
bacterial and amphibian skin peptides contain D-amino acids (Lipmann et al., 1941; Kreil et al., 1989; Richter et 
al., 1990; Kreil, 1997); and free D-amino acids have been detected in mammalian tissues and body fluids (Dunlop 
et al., 1986; Hashimoto et al., 1993; Fujii, 2002). Incorporating amino acids of opposite stereochemistry in the 
molecular design of peptides has been typically used to improve enzymatic stability and provide access to new 
molecular topologies (Nomizu et al., 1992; Zhou et al., 2002; Mahalakshmi et al., 2006).  
 Mirror image conformations are displayed by enantiomeric peptides possessing L- and D- amino acids 
(Ramachandran et al., 1963; Ramachandran et al., 1968; Kumar et al., 2010). For example, L-peptides have 
been shown to adopt right-handed α-helices (αR), and D-peptides left-handed helices (αL). In addition to chirality, 
conformation is dictated by entropy, steric factors, hydrophobic effects as well as other electrostatic interactions 
(Lubell et al., 2012). Single D-amino acid substitutions in peptides may destabilize αR-helices (Fairman et al., 
1992; Chen et al., 2002), and favor extended and turn conformations (Fabiola et al., 2001; Nagarajan et al., 
1997), in order to minimize steric clashes between side-chains. Peptides with alternating L- and D-amino acids 
have been demonstrated to adopt specific folds (Mahalakshmi et al., 2006). For example, gramicidin A, an 
antimicrobial toxin having the sequence HCO-L-Val-Gly-L-Ala-D-Leu-L-Ala-D-Val-L-Val-D-Val-L-Trp-D-Leu-L-Trp-D-
Leu-L-Trp-D-Leu-L-Trp-NHCH2CH2OH, has been shown to adopt a β-helix secondary structure, which is stabilized 
by intermolecular hydrogen bonding between strands in a head-to-head dimer (Figure 3.1; Urry et al., 1971; 
Veatch et al., 1974). Certain heterochiral peptides have been demonstrated to form right-handed and left-handed 
helical segments which self-assemble into head-to-tail tubular dimers (Ghadiri et al., 1993; Mahalakshmi et al., 
2006; Hanessian et al., 2008). In particular, even short non-cyclic constructs consisting of bis-D- and L-tripeptides 
anchored to a trans-(1R,2R)-diaminocyclohexane (C2 symmetrical turn motif) were shown to adopt energetically 
favorable local turn conformations and  helical superstructures (Hanessian et al., 2008).  
 
 
Figure 3.1. β-Helical structure of gramicidin A as depicted in cartoon (a) and stick (b) models (Generated from 
PDB ID 1AV2; Burkhart et al., 1998). 
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 In the case of 101.10, substitution of L-amino acids into the minimum active sequence of the peptide 
(tvel; Chemtob et al., 2005) was performed to probe the relationship between conformation and bioactivity. In 
particular, the D-Thr
3
-D-Val
4
 core was examined because of intriguing results using conformational constraints in 
this region (e.g. Agl and Bgl, chapter 2; Jamieson et al., 2009; Boutard et al., 2011). The β-branched nature of 
threonine and valine residues may impose van der Waals interactions causing conformational constraints of 
varying magnitude, depending on sequence chirality. In addition, threonine and valine have low propensity to 
form helical structures (Chou et al., 1978). By means of CD and NMR spectroscopy, as well as RP-HPLC, the 
substitution of D-Thr and D-Val into L-peptides has shown to strongly destabilize the amphipathic KLA-helix by 
induction of turn-like structures (Krause et al., 2000). Threonine has shown a high propensity to occupy the i+2 
position of type I β-turns, as well as the i+3 position of type VIII and type II’ β-turns (Hutchinson et al., 1994). 
Valine commonly occurs at the i+2 position of type VIII β-turns and at the i position of type I’ and II’ β-turns 
(Hutchinson et al., 1994). Computational studies of the free energy surfaces and solvation energies of Ac-(L-
Ala)3-NHMe and Ac-(L-Val)3-NHMe suggested that the weak helical propensity of valine relative to alanine may 
be in part attributed to low solvation of the valine tripeptide, which could be explained by weaker peptide-water 
interactions, stronger side-chain rotamer restriction and unfavorable steric interactions (Tobias et al., 1991). 
 In the process of developing conformationally restricted analogues of the tetrapeptide  Ac-TVAS-NH2 
(3.1; Figure 3.2), an inhibitor of plasminogen activator inhibitor-1 (PAI-1), an α-branched-α-amino-γ-lactam moiety 
(3.2) has been employed as a Thr-Val dipeptide mimic (Guzzo et al., 2002). Although the N-acetyl-3-amino-3-(1-
hydroxyethyl)pyrrolidin-2-one peptide (3.2) displayed a biological activity 10-times weaker than its parent peptide 
(3.1), this study substantiated the utility of α-amino-hydroxy-γ-lactams to study bioactive conformations of 
peptides (Guzzo et al., 2002).  
 
Figure 3.2. Tetrapeptide inhibitor of PAI-1 and a Thr-Val restrained dipeptide surrogate. 
 As alternative constrained threonine residues, 3-hydroxyproline (3-Hyp; Chakraborty et al., 2004), α-
amino-β-hydroxycyclohexanecarboxylic acid (c6Ser, Avenoza et al., 2001) and α-amino-β-hydroxy-γ-lactam (4-
hydroxy-Agl or Hgl; Sicherl et al., 2010; St-Cyr et al., 2010; St-Cyr et al., 2010b) have been utilized in peptide 
mimics (Figure 3.3). The hydroxyl group and ring in those moieties may stabilize secondary structures, 
respectively through hydrogen bonding and covalent constraints, limiting the bond rotations to specific sets of 
dihedral angles.  
 
Figure 3.3. Threonine, 3-hydroxyproline, α-amino-γ-lactam and α-amino-β-hydroxy-γ-lactam.  
Chapter 3 44 
 
 For example, (3S)-hydroxy-L-proline in the Yaa position of the repeating trimer of collagen, Yaa-Xaa-Gly, 
diminished triple-helix stability compared to L-Pro and 4-L-Hyp. The inductive effect of the hydroxyl group has 
been suggested to weaken interstrand hydrogen bonds and to cause a C
γ
-exo pucker of the pyrrolidine ring, 
leading to interstrand steric hindrance as well as improper ϕ and ψ backbone and χ side-chain torsion angles 
(Jenkins et al., 2000; Shoulder et al., 2009). Although the α-amino-γ-lactam (Agl) may restrict the ψ and ω torsion 
angles to values approaching 180º and 120º, respectively (Paul et al., 1990), the absence of side-chain 
functionality may compromise utility for threonine mimicry. Combining the conformational effects of Agl and the 
Thr side-chain, α-amino-β-hydroxy-γ-lactam (Hgl) constrains the C-terminal amide (i.e., ω), ψ and χ dihedral 
angles (Toniolo, 1990), locking the hydroxyl side chain in the gauche (+) or (-) conformers (Hruby et al., 1997). 
The analogue [(R)-Agl
3
]-101.10 (2.8; chapter 2) exhibited a CD curve characteristic of a type II’ β-turn. Moreover, 
the crystal structure of N-Fmoc-(3R,4S)-Hgl-Leu-OMe (3.3, Figure 3.4; St-Cyr et al., 2010b) exhibited dihedral 
angle geometries (ω, ϕ, ψ = 176º, -40º, 116º) similar to that of ideal type II β-turn conformation (ω, ϕ, ψ = 180º, -
60º, 120º; Hutchinson et al., 1994). 
 
Figure 3.4. β-Turn-like conformation of N-Fmoc-(3R-amino-4S-hydroxy-2-oxopyrrolidizinyl)-D-leucine methyl 
ester (3.3) observed by X-ray diffraction (reproduced from St-Cyr et al., 2010b). 
 Considering previous findings regarding the « tvel » core, in particular Agl
3
 analogues (2.8) of 101.10, a 
deeper examination of the influences of stereochemistry, side-chain and conformational restriction of the D-
heptapeptide rytvela was undertaken. Initially, the chirality at positions 3 and 4 was examined by the synthesis of 
three diastereomeric derivatives. Subsequently, the hydroxyl side-chain was replaced for an isosteric methyl 
group, employing valine of L- and D-stereochemistry to provide four double valine diastereoisomers. Finally, the 
combined consequences of side-chain and geometric constrain on biological activity were investigated by the 
synthesis of α-amino-β-hydroxy-γ-lactams of (3R,4S)- and (3S,4R)-configuration and their introduction at the 
threonine position of rytvela.  
 
3.2 Synthesis of [Hgl3]-, [Val3]- and 101.10 diastereomers 
 The synthesis of diastereomeric rytvela derivatives was performed using standard Fmoc-SPPS 
protocols (Jamieson et al., 2009), and 3.4-3.10 were obtained in high crude and isolated purity, as assessed by 
analytical RP-HPLC (Table 3.1). 
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Entry Peptide 
Crude 
purity 
%
a
 
Purity 
%
a
 
Yield 
%
b
 
HRMS
c
 
m/z  
(calcd) 
m/z  
(obsd) 
3.4 D-Arg-D-Tyr-L-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 96 > 99 9.6 850.4781 850.4780 
3.5 D-Arg-D-Tyr-D-Thr-L-Val-D-Glu-D-Leu-D-Ala-NH2 85 94 10.9 850.4781 850.4798 
3.6 D-Arg-D-Tyr-L-Thr-L-Val-D-Glu-D-Leu-D-Ala-NH2 96 > 99 13.0 850.4781 850.4755 
3.7 D-Arg-D-Tyr-D-Val-D-Val-D-Glu-D-Leu-D-Ala-NH2 84 90 6.6 848.4989 848.4989 
3.8 D-Arg-D-Tyr-L-Val-D-Val-D-Glu-D-Leu-D-Ala-NH2 85 94 14.2 848.4989 848.4968 
3.9 D-Arg-D-Tyr-D-Val-L-Val-D-Glu-D-Leu-D-Ala-NH2 90 95 7.9 848.4989 848.4975 
3.10 D-Arg-D-Tyr-L-Val-L-Val-D-Glu-D-Leu-D-Ala-NH2 87 93 9.1 848.4989 848.4982 
Table 3.1. Yields and purities of 101.10 and [Val
3
]-101.10 diastereomers. 
a
 RP-HPLC purity at 280 nm. 
b
 Yields 
after purification by RP-HPLC are based on Fmoc loading test for Rink resin. 
c
 HRMS values from the major 
protonated molecule, typically [M+H]
+
. 
 
Entry Peptide 
3.11 D-Arg-D-Tyr-(3S,4R)-Hgl-L-Val-D-Glu-D-Leu-D-Ala-NH2 
3.12 D-Arg-D-Tyr-(3S,4R)-Hgl-D-Val-D-Glu-D-Leu-D-Ala-NH2 
3.13 D-Arg-D-Tyr-(3R,4S)-Hgl-D-Val-D-Glu-D-Leu-D-Ala-NH2 
3.14 D-Arg-D-Tyr-(3R,4S)-Hgl-L-Val-D-Glu-D-Leu-D-Ala-NH2 
Table 3.2. Hgl-bearing analogues synthesized by Dr. Daniel J. St-Cyr. 
 
Figure 3.5. Structure of the analogues of 101.10 featuring Hgl residues (3.11-3.14). 
 Using an adaptation of published procedures (St-Cyr et al., 2010; Sicherl et al., 2010), analogues of 
101.10 featuring α-amino-β-hydroxy-γ-lactam (Hgl) residues (3.11-3.14) in the place of the central threonine 
residue were synthesized by Dr. Daniel J. St-Cyr. Essentially, the solution phase synthesis and purification of 
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Fmoc-Hgl-Val-Ot-Bu dipeptides from L- or D-N-(Fmoc)-oxiranylglycine methyl ester and L- or D- valine tert-butyl 
ester, followed by treatment with TFA afforded the isomerically pure dipeptide acid. Coupling of the latter to the 
N-terminus of the Rink amide resin-bound D-Glu-D-Leu-D-Ala peptide with subsequent elongation, cleavage, and 
purification following standard SPPS protocols provided peptides 3.11-3.14 (Figure 3.5).  
 
3.3  Structure-activity relationships of [Hgl3]-, [Val3]- and 101.10 diastereomers  
3.3.1  Conformational analysis  
 The influence of the modifications of 101.10 on the peptide conformation was determined by far-UV-CD 
spectroscopy in water. As previously discussed, CD curves were measured, presented as mean residue ellipticity 
versus wavelength, and analyzed using transition band values and backbone dihedral angles of relevant ideal 
secondary structures (Table 3.3). Typically, poly-L-glutamate at pH 8 (Johnson et al., 1972; Woody, 2010), 
cyclo(L-Ala-L-Ala-Aca) and cyclo(L-Ala-D-Ala-Aca) at pH 7 (Aca = ε-aminocaproic acid; Bandekar et al., 1982; 
Woody, 2010) have been used as CD standards of random coil and β-turns of type I and II, respectively. 
Secondary 
structure 
Transition bands (nm) Dihedral angles (º) 
π0  π* π1  π* n  π* ϕi+1 ψi+1 ϕi+2 ψi+2 
Type I β-
turn 
+ 190 - 202  - 220 - 60 - 30 - 90 0 
Type II’ β-
turn 
+ 190 - 205 + 225 60 - 120 - 80 0 
Table 3.3. Electronic transition bands and backbone dihedral angles of ideal type I and II’ β-turns (Hutchinson et 
al., 1994; Woody, 2010). 
 Compared to the random coil structure of rytvela (5.1), the introduction of a L-amino acid or a second 
valine at the 3- and 4-positions caused changes in CD shapes (Figures 3.6). In particular, curves indicative of a 
type I β-turn with negative maxima around 210 and 220 nm were observed for [L-Thr
3
]-101.10 (3.4), [L-Thr
3
, L-
Val
4
]-101.10 (3.6) and [L-Val
3
, L-Val
4
]-101.10 (3.10). On the other hand, curves suggestive of random coil 
conformations, albeit with a more profound negative maxima around 230 nm, were observed for [D-Thr
3
, L-Val
4
]- 
(3.8), [D-Val
3
, D-Val
4
]- (3.10), [L-Val
3
, D-Val
4
]- (3.11), and [D-Val
3
, L-Val
4
]-101.10 (3.12). These results suggest that 
inversion of only the third position stereochemistry may induce a turn conformation contingent on side-chain, 
suggesting the importance of the hydroxyl group, and that inversion of both 3- and 4-position stereochemistry 
may augment turn propensity independent of the presence of the hydroxyl group.  
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 Figure 3.6. CD spectra of a) 101.10 diastereomers 3.4-3.6 and b) Val
3
 diastereomers 3.7-3.10. 
 
Figure 3.7. CD spectra of 101.10 and α-amino-β-hydroxy-γ-lactam analogues 3.8-3.11. 
 In the case of the lactam analogue [(R)-Agl
3
]-101.10 (2.8), it exhibited a CD curve indicative of a type II’ 
β-turn with negative maximum at 205 nm and positive maximum at 225 nm (Figure 3.7). Introduction of Hgl
3
-D-
Val
4
 in 3.13 and 3.12 gave similar CD curve shapes as 2.8, characteristic of a type II’ β-turn geometry, albeit with 
a lower ellipticity, especially for the latter. The CD spectrum of 3.13 corroborated with the X-ray structure 
described above for the trans-Hgl dipeptide (3.3), which was characteristic of a type II β-turn (Figure 3.4; St-Cyr 
et al., 2010b). The CD curves for [(3S,4R)-Hgl
3
, L-Val
4
]-101.10 (3.11) and [(3R,4S)-Hgl
3
, L-Val
4
]-101.10 (3.14) 
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were similar to those observed from respective L-Val
4 
analogues (i.e., 3.7 and 3.10), with a positive and negative 
bands at 192 nm and 225 nm, respectively, suggestive of a type I β-turn.  
 Ideal type I and II’ β-turns share relatively similar backbone torsion angles, except for ϕi+1 and ψi+1 which 
differ by 120º and 90º, respectively, and give rise to CD curves that diverge only at the amide n  π* electronic 
transition (Table 3.3). It is thus not surprising that inverting the stereochemistry of the 3- or 4-position may give 
rise to either β-turn type conformations. 
 In summary, CD analysis has shown that the inversion of stereochemistry at the Val
4
 position induced in 
most cases a turn conformation and that similarly, lactams such as Agl and Hgl exhibited CD curves indicative of 
turn conformations. In addition, subtle effects were observed upon replacement of the threonine hydroxyl group 
with a methyl substituent and on addition of a hydroxyl group on the Agl ring, suggesting that contributions such 
as the hydrogen donor and acceptor properties of the alcohol as well as its inductive effects may influence 
conformation. 
 
3.3.2 Biological activity 
 The biological activity of the Thr
3
-Val
4
 analogues of 101.10 was ascertained by measuring their 
influence on two distinct IL-1β-induced effects. Their potential to modulate the stimulation of human thymocyte 
(TF-1) proliferation by IL-1β was monitored by the CyQUANT NF fluodye intercalation method, whereas their 
ability to inhibit activation of the inflammatory pathways of nuclear factor-κB (NF-κB) and mitogen-activated 
protein kinase (MAPK) by IL-1β was measured using a HEK Blue SEAP reporter gene assay. The latter relies on 
the expression and secretion of an alkaline phosphatase (SEAP) upon activation of its transcription promoter 
which is fused to activator protein (AP)-1 and NF-κB transcription binding sites, and is triggered by the binding of 
IL-1β to its membrane-bound receptor complex (IL-1RI/IL-1RAcP). The quantity of SEAP located in the 
extracellular medium is determined by adding a mixture containing the enzyme substrate (a dye termed Quanti-
Blue), which upon phosphate cleavage undergoes a change of colour, that can be accurately quantified by 
reading the optical density at 620 nm (OD620). Results are reported as the percentage of inhibition of the IL-1β-
induced effect (Figures 3.8 and 3.9).  
 Six of the seven Thr
3
-Val
4
 and Val
3
-Val
4 
diastereomers of 101.10 (3.5-3.10) exacerberated IL-1β-
stimulated thymocyte proliferation. The only exception, [L-Thr
3
]-101.10 (3.4), exhibited comparable anti-
proliferative activity (22% inhibition) to that of rytvela (19%). The Agl analogue 2.8 and all four Hgl-containing 
mimetics (3.11-3.14) displayed anti-proliferative activity. Relative to 101.10, the (3S)-Hgl analogues 3.11 and 
3.12 exhibited respectively 4.4- and 3.2-fold improved activity and the (3R)-Hgl isomers 3.13 and 3.14 retained 
similar anti-IL-1β activity. [(R)-Agl
3
]-101.10 (2.8) exhibited activity better than 101.10, yet lower than the (3S)-Hgl 
peptides relative to the Hgl series, suggesting that the (3R)-amino configuration is important to achieve inhibition 
of thymocyte proliferation. 
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Figure 3.8. Inhibition of IL-1β-induced thymocyte proliferation by Thr
3
-Val
4
 analogues, as assessed by fluodye 
intercalation. 
 
Figure 3.9. Inhibition of IL-1β-induced NF-κB and MAPK activation by Thr
3
-Val
4
 analogues, as measured via the 
HEK Blue SEAP reporter gene assay.  
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  Contrary to the results obtained in the thymocyte proliferation assay, only [L-Thr
3
]-101.10 (3.4) failed to 
block NF-κB/MAPK activation. In this test, [L-Val
4
]-101.10 (3.5) and [L-Thr
3
-L-Val
4
]-101.10 (3.6) were the most 
potent, exhibiting 99% and 69% anti-inflammatory activity, respectively. The Val
3
 analogues exhibited modest 
levels (35-41%) of inhibition of IL-1β-mediated triggering of NF-κB/MAPK pathways. Although neither the Agl nor 
Hgl analogues exhibited improved activity relative to rytvela (83% inhibition) in the NF-κB/MAPK assay, they did 
exhibit 20-61% inhibition, with the (R)-Agl analogue 2.8 displaying higher activity than the Hgl counterparts. 
 The different activities of the analogues towards inhibition of IL-1β-induced thymocyte proliferation and 
NF-κB/MAPK activation is notable and may be attributed to several factors: a) the two assays are measuring the 
effects of analogues at two different phases of the IL-1β-mediated response; b) the two assays are monitoring 
distinct physiological effects of IL-1β, namely immune cell proliferation (part of the adaptive immune response) 
and activation of inflammatory pathways (part of the inflammatory/destructive reaction); and c) the conformational 
changes induced upon binding of a peptide to the IL-1RI may be distinct from one analogue to the other, and 
may thus modulate the receptor differently causing biased signaling. Therefore, the divergent results may attest 
of the functional selectivity of different pharmacophores for causing anti-immune and anti-inflammatory effects.  
 
Figure 3.10. Structure-activity relationships observed using [Hgl
3
]-, [Val
3
]- and 101.10 diastereomers. 
 
3.4 Concluding remarks 
 Attempting to correlate the relationships between structure, conformation and biology of 101.10, a series 
of Thr
3
-Val
4
 analogues were prepared, and CD studies were performed and complemented by two in vitro 
assays. Notably, many analogues demonstrated divergent bioactivity and differing states of efficacy in the two 
assays. Peptidomimetics that blocked more efficiently NF-κB/MAPK activation contained either L-Val
4
 or (3R)-
Hgl
3
 residues and exhibited β-turn-like CD curves. Alternatively, the analogues that showed the highest inhibition 
of IL-1β-induced immune cell proliferation possessed L-Thr
3
 and (3S)-Hgl
3
 residues, and also displayed CD 
spectra indicative of β-turns. In general, substitution of D-Thr
3
 by L- or D-Val
3
 caused a loss of activity in both 
assays, suggesting that the hydroxyl side-chain is important for eliciting bioactivity. With respect to changes in 
stereochemistry, L-Thr
3
 (3.4) and L-Val
4
 (3.5) exhibited respectively losses of activity in the NF-κB/MAPK 
activation and proliferation relative to 101.10, differentiating the anti-IL-1β effects. Finally, conformational 
constraint from the application of lactams generally gave peptidomimetics with inhibitory activity to both NF-
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κB/MAPK activation and proliferation, albeit their potency relative to 101.10 was contingent on the assay 
employed as well as ring system structure and stereochemistry.   
 Selected Thr
3
-Val
4
 analogues are currently being tested for their inhibitory potency (IC50) toward NF-
κB/MAPK activation and in in vivo inflammatory models, such as IL-1β-mediated hyperthermia and contact 
dermatitis, as well as oxazolone-induced arthritis. These ongoing studies may help clarify the structure-activity 
relationships between the Thr
3
-Val
4
 subunit of rytvela and explored IL-1β-mediated pathways.   
 
3.5  Experimental section 
3.5.1 General 
 See experimental section of chapter 2. 
 
3.5.2 Characterization and purification 
 Refer to experimental section of chapter 2. 
  
3.5.3 Synthesis of peptides and mimetics by standard Fmoc-SPPS 
 See experimental section of chapter 2. 
 
3.5.4  Ultraviolet-circular dichroism 
 Refer to experimental section of chapter 2. 
 
3.5.5 Biological activity screening of analogs  
3.5.5.1  CyQUANT intercalation assay 
 Same as experimental section of chapter 2. 
 
3.5.5.2 HEK Blue SEAP reporter gene assay 
 Activation of the NF-κB pathway upon interaction with IL-1β or IL-33 receptor complex at the membrane 
was assessed via HEK-Blue SEAP reporter gene assay (InvivoGen, California, USA). Basically, HEK Blue IL-
33/IL-1β sensor cells (stably expressing the SEAP reporter gene; InvivoGen, California, USA) were cultured in 
growth medium made of complete Dulbecco’s modified Eagle medium (DMEM; 4.5 g/L glucose, 2 mM L-
glutamine, 100 mM sodium pyruvate, 10% fetal bovine serum, 50 U/mL penicillin, 50 µg/mL streptomycin; Gibco 
(Invitrogen), Ontario, CA) supplemented with selection antibiotics (30 μg/mL Blasticidin, 200 μg/mL HygroGold 
and 100 μg/mL Zeocin; InvivoGen, California, USA). Upon reaching almost 70% confluency, HEK Blue cells were 
reincorporated into complete DMEM medium and split (2.5x10
4
 cells in 180 µL/well) into 96-well membrane-
treated flat bottom culture plates (#3595, Corning Life Sciences, Massachusetts, USA). Cells were pre-treated 
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with 10 µL of peptide or peptidomimetic (1 µM) for 15 min., after which 10 µL of human IL-1β (2.5 ng/mL, 
PeproTech, New Jersey, USA) was added. After 24 h of incubation, 40 µL of supernatant was added to a UV-
transparent 96-well plate (#3635, Corning Life Sciences, Massachusetts, USA) already filled with 160 µL of 
resuspended Quanti-Blue dye (InvivoGen, California, USA). The plate was covered and incubated for 20 min. 
The level of SEAP was measured by reading absorbance (or optical density, OD) at 620 nm using a multiplate 
reader equipped with a monochromator (Perkin Elmer Wallac Envision 2104; Perkin Elmer, California, USA). 
Hexaplicates results were normalized over complete DMEM  background signal and analyzed by one-way 
analysis of variance (ANOVA) factoring for treatments, and data are presented as mean ± standard error of the 
mean (SEM). 
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CHAPTER 4 
Indolizidinone Amino Acids 
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4.1 Introduction 
 Indolizidin-2-one amino acids (I
2
aa; Figure 4.1a) are bicyclic lactams that include an Ala-Pro-type 
dipeptide unit with an all-carbon backbone. The popularity of these azabicyclo[3.4.0]nonane amino acids has 
quickly progressed after a [6,5]-fused thiaindolizidinone (called BTD, 4.1) was shown to serve as a type II’ β-turn 
mimic, contingent upon ring-fusion and backbone stereochemistry, which was comparable to D-Ala-L-Pro 
dipeptide (4.2; Nagai et al., 1985; Nagai et al., 1993). However, the higher acidic stability of I
2
aa compared to its 
thia and oxa counterparts has rendered it an attractive rigid [6,5]-fused peptidomimicry system. 
 
Figure 4.1. (3S,6S,9S)-I
2
aa as dihedral angles constraint (a), and typical residue position in γ-turn (b) and β-turn 
motifs (c) (adapted from Halab et al., 2000).  
 
Figure 4.2. Structure of type II’ β-turn mimics [6,5]-thiaindolizidinone and D-Ala-L-Pro dipeptide. 
 The I
2
aa heterocycle restricts three contiguous dihedral angles, ϕ2, ψ1 and ω1. Moreover, the torsion 
angles ϕ1 and ψ2 are confined by gauche interactions with the ring system (Figure 4.1a; Hanessian et al., 1997; 
Halab et al., 2000). The conformational preferences elicited by these restrictions have been studied by 
spectroscopic and crystallographic methods supported by computational analysis. Using N-acetyl-I
2
aa-9-
methylamide models, force fields evaluating the frequency of hydrogen bond formation have calculated that the 
minimal energy conformers of the dipeptide may preferentially adopt a γ- or β-turn (Lombart et al., 1996b; 
McDonald et al., 1996; Takeuchi et al., 1998). For example, the dihedral angles for both (3S,6S,9S)- and 
(3S,6R,9S)-I
2
aa N-acetyl-methylamide dipeptides were respectively characteristics of inverse and classical γ-
turns, as well as type II’ and II β-turns (Table 4.1; Cluzeau et al., 2007). The circular dichroism spectrum of Dnp-
Gly-(3S,6S,9S)I
2
aa-Gly-p-NA (Dnp = N-2,4-dinitrophenyl; p-NA = para-nitroanillide) exhibited a curve bearing a 
positive band at 305 nm and a negative maximum at 350 nm, indicative of a type II’ β-turn (Lombart et al., 1997; 
Halab et al., 2000). The close similarity between the dihedral angles obtained from the X-ray diffraction of N-Boc-
I
2
aa-esters crystals (Lombart et al., 1996; Polyak et al., 1998; Polyak et al., 2000) and that of ideal turn 
conformations (Table 4.1) corroborated the high turn-propensity of these azabicycloalkanes (Ball et al., 1990, 
Nagai et al., 1993). Together, these investigations have denoted the positioning preferences of I
2
aa, namely at 
the i and i+1 residue of a γ-turn, and at the i and i+1 or at the i+1 and i+2 positions of a β-turn (Figure 4.1b and c; 
Lombart et al., 1996b; Halab et al., 2000). 
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Secondary 
structure 
Transition bands (nm) Dihedral angles (º) 
π0  π* π1  π* n  π* ϕi+1 ψi+1 ϕi+2 ψi+2 
classical γ-
turn 
+ 198 - 212 + 230 75 - 64 - - 
type II’ β-
turn 
+ 190 - 205 + 225 60 - 120 - 80 0 
PPI + 190 - 205 - 220 - 75 160 - - 
PPII - 205 - + 228 - 75 145 - - 
Table 4.1. Electronic transition bands and backbone dihedral angles of ideal classical γ-turn, type II’ β-turn, PPI 
and PPII (Rose et al., 1985; Hutchinson et al., 1994; Uray et al., 2000; Moradi et al., 2009; Woody, 2010). 
 Since 1994, azabicyclo[3.4.0]alkanone amino acids have been regularly used to study peptide 
conformation-activity relationships (Figure 4.3.). For example, replacement of the D-Phe-Pro dipeptide residues 
with (3R,6R,9R)- and (3S,6S,9S)-I
2
aa (4.4) in the cyclic peptide drug gramicidin S (GS, cyclo[Val-Orn-Leu-D-Phe-
Pro]2, 4.3) produced analogues which were shown by CD and NMR spectroscopy to adopt the type II’ β-turn/anti-
parallel β-sheet structure of the parent peptide. Moreover, the [I
2
aa
4-5,4’-5’
]-GS analogues (4.4) displayed anti-
microbial activity, albeit with higher minimal inhibitory concentration (MIC) against Gram-negative bacteria and 
fungi than the parent compound (Roy et al., 2002). In addition, unsaturated (3S,6S)-I
2
aa equivalent 4.6 has been 
used to probe the bioactive conformation of thyrotrophin-related hormone (TRH). Relative to the poorly active 
[Cha
2
]-TRH analogue (4.5), the azabicyclo[4.3.0]non-2-ene derivative 4.6 improved 3.4- and 4.7-times the 
receptor affinity and potency in stimulating inositol phosphate second messenger, respectively (Laakkonen et al., 
1996; Li et al., 1996), offering potential therapeutic avenues to treat thyroid disorders. In the development of 
calcitonin gene-related peptide (CGRP) antagonists as potential treatments of neuronal pain, [D
31
, I
2
aa
33-34
, F
35
]-
CGRP27-37 (4.8) displayed 7-fold improved potency relative to the active peptide fraction [D
31
, F
34
, F
35
]-CGRP27-37 
(4.7), in an inhibition assay of α-CGRP-induced production of cyclic adenosine monophosphate (cAMP; Boeglin 
et al., 2007).  
 In preliminary studies, [D-Pro
4
]-101.10 exhibited anti-inflammatory activity, both in vitro and in vivo. An 
Ala-Pro-type bicyclic scaffold such as I
2
aa was thus employed to investigate the spatial arrangement of 
pharmacophores, stereochemistry and conformation at the 3- and 4-positions of rytvela. Accordingly, a series of 
analogues of 101.10 were synthesized bearing a central indolizidin-2-one amino acid and proline residues. 
 
4.2  Synthesis of indolizidinone amino acids 
4.2.1 Previous synthetic approaches 
 A number of strategies (Cluzeau et al., 2005) have been adopted to construct indolizidin-2-one amino 
acids, in which obtaining the correct absolute stereochemistry at all three carbon centers was the key issue. 
Although the best starting material appears as cyclic amino acid templates such as proline or pyroglutamic acid, 
the first syntheses of I
2
aa relied on acyclic precursors. For example, a diastereoselective synthesis employed a 
Sköllkopf alkylation to prepare a linear diamino acid dicarboxylate precursor (4.9), which upon reductive 
amination and lactam formation gave a separable mixture of the (3S,6S,9S)-[5,6]-fused bicycle (4.10), along with 
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the (3R,6R,9R)-enantiomer and a racemic mixture of the diastereomers (Scheme 4.1; Mueller et al., 1994). A 
similar linear precursor (4.11) was prepared by a Horner-Emmons olefination and enantioselective hydrogenation 
using a chiral rhodium catalyst, and used subsequently in a reductive amination/lactamization sequence to 
furnish the desired bicyclic lactam (4.12, Scheme 4.2; Wang et al., 2001). Anodic amide oxidation and 5-position 
functionalization has given 5-vinylproline methyl ester (4.13), which after coupling to N-Boc-vinylglycine 4.14,  
olefin metathesis and hydrogenation provided the N-Boc-(3S,6S,9S)-I
2
aa 4.15 (Scheme 4.3; Beal et al., 2000).  
 
Figure 4.3. (3S,6S,9S)-I
2
aa analogues of gramicidin S, cyclohexylalanine-thyrotropin-related hormone ([Cha
2
]-
TRH) and modified calcitonin gene-related peptide ([D
31
, P
34
, F
35
]-CGRP27-37). 
 Many published synthetic approaches towards the indolizidin-2-one amino acids have met the 
challenges of creating the bicycle with good stereocontrol by employing enantioselective and diastereoselective 
methods (Hanessian et al., 1996; Kim et al., 1997; Hanessian et al., 2000; Mulzer et al., 2000; Wang et al., 2001; 
Hanessian et al., 2003) as well as by application of amino acids derived from the chiral pool (Mueller et al., 1994; 
Lombart et al., 1996; Polyak et al., 1998; Halab et al., 2000; Beal et al., 2000). However, methods are more rare 
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which provide selective and combinatorial access to all stereoisomers of the bicycle in good yields (at most 80%) 
(Lombart et al., 1996; Mulzer et al., 2000).  
 
Scheme 4.1. Synthesis of I
2
aa via Sköllkopf alkylation and reductive amination (Mueller et al., 1994). 
 
Scheme 4.2. Synthesis of I
2
aa via Horner-Emmons olefination and asymmetric hydrogenation (Wang et al., 
2001). 
 
Scheme 4.3. Synthesis of I
2
aa via anodic amide oxidation and ring-closing metathesis (Beal et al., 2000). 
 
4.2.2 Our synthetic methodology  
 (3R,6R,9R)-Indolizidinone amino acid 4.17 was synthesized in solution from D-glutamic acid (4.16) using 
a Claisen condensation/reductive amination/lactam cyclization sequence (Scheme 4.4; Lombart et al., 1996). A 
modification of the original published method (Lombart et al., 1996) was employed in the hydrogenation of the 
symmetric ketone: instead of a bulk reactor, flow-through hydrogenation was performed in a H-Cube® apparatus, 
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which produces molecular hydrogen from the electrolysis of water. This change resulted in a reduction of the 
reaction time from 2-3 days down to 30 min. The safety of the operation was improved by circumventing the use 
of a pressurized hydrogen tank. Conversions and yields were similar if not superior to that of published method 
(81%; Lombart et al., 1996).  
 The Boc group of (3R,6R,9R)-indolizidinone N-(Boc)amino acid was substituted for a Fmoc N-protecting 
group (Boeglin et al., 2007). N-Fmoc-(3R,6R,9R)-indolizidinone amino acid 4.18 was introduced at the Thr
3
-Val
4
 
positions of 101.10, employing standard peptide synthesis protocols on Rink amide MBHA resin (Scheme 4.5). 
The indolizidinone peptides were recovered in 47-96% crude purity, as assessed by analytical HPLC, and 
generally isolated in > 95% purity in 5.3-14.5% yield (Table 4.2). For comparison, three peptides containing a 
Pro
4
 residue were prepared using standard SPPS protocols (Table 4.2.).  
 
Scheme 4.4. Solution-phase synthesis of the indolizidin-2-one dipeptide building block. 
 
Scheme 4.5. Anchoring of N-Fmoc-(3R,6R,9R)-I
2
aa on Rink MBHA resin following standard SPPS protocols. 
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Entry Peptide 
Crude 
purity 
%
a
 
Purity 
%
a
 
Yield 
%
b
 
HRMS
c
 
m/z  
(calcd) 
m/z  
(obsd) 
4.19 D-Arg-D-Tyr-(3R,6R,9R)-I
2
aa-D-Glu-D-Leu-NH2 80 99 8.4 759.4148 759.4114 
4.20 
D-Arg-D-Tyr-(3R,6R,9R)-I
2
aa-D-Glu-D-Leu-D-
Ala-NH2 
47 95 5.3 830.4519 830.4493 
4.21 
D-Arg-D-Tyr-D-Thr-D-Pro-D-Glu-D-Leu-D-Ala-
NH2 
85 92 10.2 848.4625 848.4619 
4.22 
D-Arg-D-Tyr-D-Thr-L-Pro-D-Glu-D-Leu-D-Ala-
NH2 
96 > 99 14.5 848.4625 848.4598 
4.23 D-Arg-D-Tyr-D-Thr-D-Pro-D-Glu-D-Leu-NH2 88 > 99 7.0 777.4254 777.4273 
Table 4.2. Yields and purities of I
2
aa- and Pro-containing analogues of 101.10. 
a
 RP-HPLC purity at 280 nm. 
b
 
Yields after purification by RP-HPLC are based on Fmoc loading test for Rink resin. 
c
 HRMS values from the 
major protonated molecule, typically [M+H]
+
. 
 
 
Entry 
Peptide
a
 
4.24 D-Arg-D-Tyr-(3S,6S,9S)-I
2
aa-D-Glu-D-Leu-D-Ala-NH2 
Table 4.3. [(3S,6S,9S)-I
2
aa]-101.10 synthesized by Carine Bourguet. 
  
4.3  Structure-activity relationships of indolizidinone amino acids 
4.3.1 Conformational analysis  
 The ability of proline and indolizidin-2-one amino acid residues to elicit folding in 101.10 analogues 4.19-
4.24 was assessed by far-UV-CD spectroscopy in water. The CD data were reported as mean residue ellipticity, 
[θ] (Figure 4.4), and analyzed according to typical CD electronic transition values (Table 4.1).  
 Examination of the CD spectra of analogues possessing proline or I
2
aa moieties showed limited 
changes in curve shape from the parent peptide. For example, [(3R,6R,9R)-I
2
aa]-101.10 (4.20) exhibited a CD 
curve similar to the parent peptide, indicative of a disordered structure. Truncating the alanine of this analogue 
(4.19) resulted in the deepening of the negative shoulder at 202 nm, suggesting discrete amounts of PPII. The 
CD spectra of the (3S,6S,9S)-I
2
aa
 
(4.24)
 
displayed a positive band at 198 nm and a negative band at 222 nm, 
characteristic of a PPI helical structure. Replacing D-Val for L- or D-Pro with or without removal of D-Ala (4.21-
4.23) produced curves featuring two negative maxima at 203 and 225-230 nm intersperced with a positive apex 
centered at 215-220 nm, indicating the presence of a type I β-turn. Overall, these results suggested that a central 
Pro or a I
2
aa
 
residue of the (S)-stereochemistry induced more profound changes in the CD curve of the parent 
peptide than their (R)-counterparts, and that most of these analogues elicited a turn or a polyproline-type helical 
conformation, albeit in discrete amounts for some mimetics. 
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Figure 4.4. CD of 101.10  and a) selected I
2
aa and b) Pro
4
 analogues. 
 Although the CD spectrum of [(3R,6R,9R)-I
2
aa
3,4
, ΔAla
7
]-101.10 (4.19) indicated the slight presence of 
PPII, discerning between PPII and unfolded states has been typically problematic, because both structures lack 
hydrogen bonding, are highly dynamic and are indistinguishable by 
1
H-NMR spectroscopy (Bochicchio et al., 
2002). In nature, type II poly-L-proline is a left-handed helix composed of three prolyl residues per turn with 
defined backbone dihedral angles (ϕ, ψ, ω = −75°, 145°, 180°), commonly found in elastomeric proteins such as 
collagen and elastin. In the Ramachandran plot, the PPII structure is located very close to type II β-turn and 
extended conformations (Bochicchio et al., 2001), and in circular dichroism, only a slight shift in the nπ* and 
π0π* electronic transitions as well as a faint peak at 220 nm may distinguish PPII from random coil. The PPII 
has thus been considered an extended structure coexisting with unordered conformations as well as turn motifs. 
Other extensive studies have noted the close resemblance between CD spectra of unordered, PPII and collagen 
(Tiffany et al., 1968), and suggested that the so-called random coil may consist in short segments (4-6 residues) 
of PPII helices mixed with sharp bends, a motif referred to as ʺPPII helix-coilʺ (Bochicchio et al., 2002). In order to 
unambigously reveal PPII as the dominant solution conformer of a peptide, further spectroscopic studies 
including vibrational circular dichroism (vCD), Raman optical activity (ROA) and low-temperature CD, must be 
conducted. However, none of these techniques were in our hands, and only suppositions about the incidence of 
PPII in the ensemble of aqueous conformers of [(3R,6R,9R)-I
2
aa analogue 4.19 could be made.   
 
 
 
4.3.2 Biological activity 
 The anti-IL-1β activity of the indolizidin-2-one and proline analogues (4.19-4.24) was measured in 
human thymocyte proliferation and NF-κB and MAPK pathways activation (Figure 4.5), as described in previous 
chapters. 
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Figure 4.5. Inhibition of IL-1β-induced thymocyte proliferation (a) and NF-κB/MAPK activation (b) by I
2
aa (4.19, 
4.20, 4.24) and Pro
4
 analogues (4.21-4.23), as measured by fluodye intercalation and HEK Blue SEAP reporter 
gene assays, respectively.  
 The non-redundancy in anti-IL-1β activities of rytvela will be discussed in more details in chapter 5. The 
replacement of valine by D-proline (4.21) had a beneficial effect in the SEAP reporter gene test, regardless of the 
truncation of the C-terminal residue (4.23), exhibiting an average increase in 40% of IL-1β inhibition. On the 
contrary, employing L-proline produced a peptide (4.22) with approximately no observable influence on IL-1β 
effects. The (3S,6S,9S)-I
2
aa mimetic 4.24 demonstrated no significant effect on immune cell proliferation, and a 
modest 29% reduction of NF-κB/MAPK pathway induction; results that were similar to its enantiomeric bicyclic 
analogue (4.20), which produced no significant change in both assays. Removal of the alanine yielded the most 
active analogue of this series, [(3R,6R,9R)-I
2
aa
3,4
, ΔAla
7
]-101.10 (4.19), exhibiting 1.4- and 4-fold increase in 
anti-IL-1β actions compared to rytvela (5.1). Overall, the biological screening of these analogues suggested that 
the (R)-stereochemistry either for the proline or the bicycloalkane retained or improved anti-IL-1β activity 
compared to rytvela.  
 
Figure 4.6. Structure-activity relationships regarding the I
2
aa
3,4 
and Pro
4
 analogues of 101.10. 
 
Chapter 4 63 
 
4.4 Concluding remarks 
 Introducing a proline at the fourth position of 101.10 produced peptides (4.21-4.23) that demonstrated 
increasingly more intense CD curves characteristic of a type I β-turn, whereas introducing a I
2
aa dipeptide at the 
third and fourth positions yielded analogues (4.19, 4.20, 4.24) revealing the increasing presence of polyproline-
like folds, contingent on the stereochemistry. For example, using the (3S,6S,9S)-scaffold may push the amide 
bond towards the cis-conformation, which favour PPI helices (Moradi et al., 2009). On the contrary, both 
(3R,6R,9R)-bicycles elicited CD curves suggestive of PPII structures, which are typically formed by trans-amide 
isomers. Stereochemistry of the scaffolds turned out to be crucial on the bioactivity: for example, employing the 
D-proline or (3R,6R,9R)-azabicycloalkanone produced analogues (4.19, 4.22, 4.24) with higher anti-IL-1β in vitro 
activities than their L- and (3S,6S,9S)-counterparts (4.22, 4.24). Truncating the alanine in the peptides resulted in 
more intense transition bands in the CD spectra and good to superior anti-IL-1β activities, relative to 101.10 and 
heptamers. Particularly, ry-(3R,6R,9R)-I
2
aa-el (4.19) was the only mimetic of all series to demonstrate 
consistently high inhibition of both IL-1β-mediated effects.  
 The structure-activity relationships regarding the I
2
aa
3,4 
and Pro
4
 analogues of 101.10 (Figure 4.6) 
correlate with the trends observed for the Thr
3
-Val
4
 and Hgl
3
 mimetics (chapter 3). In all cases, the D- and (R)-
configurations at the central 3- and 4-positions appear crucial to impart activity against IL-1β.  
 
Figure 4.7. New aminoalkanoyl derivative (4.25) of [(3R,6R,9R)-I
2
aa
3,4
, ΔAla
7
]-101.10 (4.19) which displayed 
promising anti-IL-1β efficacy as well as physicochemical properties relative to rytvela. 
 Among all, [(3R,6R,9R)-I
2
aa
3,4
, ΔAla
7
]-101.10 (4.19) emerged as a small, potent anti-IL-1β analogue of 
the parent peptide, from which a subsequent library of α- and β-amino-γ-lactams as well as aminoalkanoyl 
derivatives was synthesized, and interesting preliminary biological data were obtained. Moreover, further 
pharmacological characterization of these analogues compared to rytvela has been recently undertaken, 
including in vitro assessment of solubility, permeability and biostability, as well as in silico calculation of ADMET 
properties such as lipophilicity, ionizability and polar surface area. For example, the insertion of the indolizidin-2-
one amino acid into the 101.10 sequence has improved the partition coefficient (C log P) from -3.0558 to -2.6836, 
and the Connolly solvent excluded volume (molecular surface) from 581.023 to 530.578 Å
3
, as obtained via the 
chemical standard properties calculator of the GAMESS software. In addition, the in vitro permeability of 
[aminohexanoyl
1
, (3R,6R,9R)-I
2
aa
3,4
, ΔAla
7
]-101.10 (4.25; Figure 4.7) was 7- and 1.6-times higher than rytvela 
(5.1) at pH of 4.0 and 7.4, respectively, as measured in a parallel artificial membrane permeability assay 
(PAMPA). In light of these findings, the optimization of 101.10 employing (3R,6R,9R)-indolizidin-2-one as a rigid 
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surrogate has resulted into a small IL-1β antagonist that displayed improved in vitro efficacy, permeability, and 
chemophysical properties, as well as a CD curve typical of a poly-D-proline type II fold.  
 
4.5  Experimental section 
4.5.1 General 
 See experimental section of chapter 2. 
 
4.5.2 Characterization and purification 
 Refer to experimental section of chapter 2. 
  
4.5.3 Solution-phase synthesis of I
2
aa dipeptide 
 Essentially, the solution-phase synthesis of the indolizidin-2-one scaffold was performed as previously 
described (Lombart et al., 1996), except for the hydrogenation step. 
 
4.5.4 Hydrogenation chemistry 
 Flow-through hydrogenations were conducted in a H-Cube® continuous-flow hydrogenation reactor 
(Thales Nano, Budapest, Hungary) equipped with an autosampler, liquid handler, hydrogen generator, product 
collector and multi-chambers hydrogenation head. Upon mixing with a pressurized flow of hydrogen, sample 
solutions are pushed through a teflon-coated system toward a packed catalyst cartridge (CatCart®, Thales Nano, 
Budapest, Hungary), where heating and pressure can attain 100 bar and 100°C, respectively. Precisely, a 
solution of (2R,8R)-dimethyl-5-oxo-2,8-bis[N-(PhF)amino]azelate (7.6 mg, 0.016 mmol) in anhydrous THF (2.7 
mL) and glacial AcOH (0.3 mL) was stirred for 10 min., filtered through a Chromspec 0.2 µm filter, and 
transferred into a 5-mL glass sample vial. The H-Cube® system was washed for 10 min. with the eluting solvent 
(10% AcOH in THF), after which the 10 wt% Pd/C cartridge (30 mm, CatCart®, Budapest, Hungary) was primed 
for 10 min. The azelate sample solution was injected at 0.3 mL/min., and subsequently eluted for 30 min. in the 
collection vials using the same flow rate, at a hydrogen pressure around 40 bar and 30°C. The combined 
collection solutions were dried in vacuo after which the residual solids were dissolved in MeOH (1 mL) and stirred 
for 24 h. The solvolysed product, (3R,6R,9R)-aminoindolizidinone methyl ester 4.17, was evaporated to a residue 
that was directly used in the next reaction. 
 
4.5.5 Synthesis of peptides by standard Fmoc-SPPS 
 See experimental section of chapter 2. 
 
4.5.6 Ultraviolet-circular dichroism 
 Refer to experimental section of chapter 2. 
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4.5.7 Biological screening of analogues  
 See experimental section of chapters 2 and 3. 
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5.1  Introduction 
 Ionizable molecules dissociate into two or more ions in solution. Typically, the simpler ion of a metal 
complex or a charged amino acid is designated as the counter-ion. In principle, every acid or base can partake in 
salt formation, including pharmaceuticals such as peptides and proteins. Emerging evidence has demonstrated 
that a drug’s counter-ion is an important facet of the pharmaceutical (Berge et al., 1977; Stahl et al., 2002; Kunz, 
2010), and may be tuned to impart desired chemical, biological and physical characteristics to the drug. Even in a 
medium of high dielectric constant, counter-ions may modulate drug efficacy, receptor engagement, cell or 
nuclear penetration, and changes in protein conformation, contingent on the specific type of ion used. Various 
salts produced from the same drug rarely diverge pharmacologically; however, their physicochemical properties 
may be influenced, including dissolution rate, solubility, permeability, stability and hygroscopicity (Berge et al., 
1977; Stahl et al., 2002).  
 The counter-ion has been proposed to assist in the passive transport of drugs. For example, a 
hydrophobic counter-ion, such as trifluoroacetate or hexafluorophosphate, may help overcome the energy 
barriers required to insert into the internal lipophilic phase of the phospholipid bilayer membrane (Esbjorner et al., 
2007). Changes in counter-ion may similarly affect the ampiphilicity of a drug with pH, and facilitate passage in 
the gastrointestinal (GI) tract upon oral absorption (Baciu et al., 2006). Studies on the octanol/water partitioning 
of charged species, including zwitterions and ordinary ampholytes, have demonstrated that ionic molecules must 
be accompanied by their ion-pair to enter a lipid phase such as octanol (Adjei et al., 1993). Counter-ion may thus 
effect drug partitioning, as observed in lipophilicity profiles (log D versus pH graph). For example, the log D of the 
dipeptide L-Trp-L-Phe was systematically higher in a 1.0 M KCl solution than in pure aqueous solution, and 
switching for a 1.0 M NaClO4 solution reduced significantly the log D compared to the KCl electrolyte, yet 
maintained a value better than the aqueous level (Avdeef, 2001).  
 Different salts may improve stability of a parent compound by a variety of mechanisms (Kunz, 2010). For 
example, sparingly soluble salts may be used in the formulation to reduce the dissolution of a drug in solution, 
and thereby avoid degradation in the medium. For example, penicillin G (BenPen), a broadly used antibiotic, 
displays characteristic solution instability; however, degradation was minimized by respectively employing 
procaine, benzathine, and hydrabamine as counter-cation (Schwartz et al., 1960). Counter-ions may also affect 
the dissolution rate of a drug by shifting the dissolution equilibrium of the solute. Salts will usually speed 
dissolution by acting as their own buffers to alter the pH of the inner diffusion layer, which contributes to increase 
the solubility of the parent compound. For ions typically encountered in physiological systems (Cl
-
, K
+
, Na
+
), the 
common ion effect may, however, hamper dissolution of the salt, due to the pre-existing abundance of the ion in 
the medium (Shozo et al., 1980). In general, salts possess greater absorption and higher oral exposure than their 
free acid/base counterparts, and their usage in drug formulation has been beneficial for a large array of drugs 
(Kerns et al., 2008). 
 Different types of ions may affect distinctly the solubility and stability of secondary and tertiary structures 
of proteins (Horowicz, 1964). The order of extent of these effects correlates with the original Hofmeister series 
(Hofmeister, 1890; Collins et al., 1985), which ranked ions according to their ion-pairing effectiveness (also 
referred to as their ʺsalting inʺ capacity). Accordingly, fluorine and sulfate detain the weakest ion-pairing 
capability; phosphate, formate and acetate exhibit medium ion-pairing capability; and larger halides, 
trifluoroacetate, chlorate and perchlorate show the strongest ion-pairing effectiveness (Kunz, 2010).  
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 Only some anions and cations are pharmaceutically acceptable (FDA-approved) for employment in drug 
formulation, because of their physicochemical properties. The most common counter-anions occurring in the 
Cambridge Structural Database (Haynes et al., 2005) are chloride (45.5%), bromide (21.2%), nitrate (4.4%), 
sulfate (dianionic; 2.4%), tosylate (1.8%), phosphate (monoanionic; 1.5%), L-tartrate (monoanionic; 1.3%), 
maleate (1.1%) and acetate (Figure 5.1).  
  
Figure 5.1. Most common counter-anions occurring in the Cambridge Structural Database (Haynes et al., 2005).  
 In the context of 101.10, counter-ion effects may influence the properties of the cationic peptide. 
Although accurate determination of the ionic state of 101.10 at a physiologically relevant pH may be 
accomplished by measurement of the isoelectric point of the peptide via potentiometric titration, significant 
amounts of material would be required. Alternatively, the ionization state of 101.10 at a pH of 4 (0.1% FA in H2O) 
may be ascertained by examination of the MS data, in which the bicationic specie (charged arginine and amino-
termini, uncharged glutamate) accounted for 60% of the m/z signal compared to 40% for the monocation. At least 
one anion may thus be presumed to associate with 101.10 in solution. Concern for the counter-ion of 101.10 was 
raised after diverging biological activities were obtained from different synthetic sources of the peptide, for which 
HPLC-MS analyses of different samples revealed differences in purity depending on the source. For example, a 
sample of 101.10 purchased from Elim Biopharmaceuticals (5.9, Table 5.3), was shown by HPLC-MS analysis to 
contain 61% of rytvela, 24% of ytvela, and 15% of rytvelaa, all as their respective trifluoroacetate salts (data not 
shown). In the synthesis of peptides, the chiral amino acid building blocks may contain appreciable quantities of 
its enantiomer, such that impure samples of peptides may also contain inseparable diastereoisomers, which elute 
at similar retention times. 
 In order to decipher the active pharmaceutical ingredient and optimal counter-ion, pure rytvela was 
synthesized following Good Manufacturing Practices (GMP) for peptide synthesis, and transformed into three 
different salts: formate (FA), acetate (OAc) and trifluoroacetate (TFA). Furthermore, the main synthetic impurities 
were synthesized and purified using standard solid-phase peptide synthesis procedures. In addition, the retro, 
enantio, and retro-enantio isomers of 101.10 were prepared to probe the residue configuration and backbone 
direction requirements to impart bioactivity (see section 1.4.2.1). 
 
5.2  Synthesis, ion-exchange and CZE analysis of analogues 
5.2.1  GMP synthesis of rytvela 
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 The optical purity of the Fmoc-amino acid building blocks was initially assessed by examining specific 
rotations at 589 nm, which correlated with their theoretical values. The initial loading of the resin was determined 
in two parallel assays (employing DBU and piperidine), which yielded similar values. Completion of the coupling 
of the first amino acid was also measured by the two same assays. Although the measured value differed slightly 
from that expected, chain elongation was initiated. Considering a manufacturing scale of rytvela, the synthesis 
was targeted on 0.3 mmol, employing ecofriendly solvents, such as iso-propanol and di-iso-propylether, instead 
of their shorter alkyl counterparts. After each deprotection and coupling step, a Kaiser test was performed. In the 
middle of the sequence, a small quantity of resin was cleaved and analyzed by HPLC-MS to ascertain the sample 
quality.  
 Relative to standard SPPS procedures, reduced equivalents of di-iso-propylethylamine (DIEA) were 
used during coupling steps to reduce the occurrence of in situ Fmoc-deprotection by the base, and double 
coupling of amino acid. The double coupling problem was observed in the sample from Elim Biopharmaceuticals, 
in which the D-octapeptide rytvelaa was detected. In the synthesis of rytvela on an automatic peptide synthesizer 
using typical amounts of base, some double coupling of alanine was also observed. The large presence of the 
truncated D-hexapeptide ytvela in the chromatogram of 101.10 obtained from commercial and internal sources 
indicated that the last amino acid, Fmoc-D-Arg(Pbf)-OH, was difficult to couple. In our hands, this coupling 
required the resin to be submitted to a second reaction with freshly made solutions, for a longer period of time. 
 The crude purity of this rytvela was calculated as 85% using HPLC-MS with UV detection at 280 nm 
(5.1; Table 5.1), contaminated with 5% of truncated peptide, ytvela (5.2). The crude yield was approximated at 
94%. A more profound characterization of the impurities contained in the crude sample of 101.10 was made by 
HPLC-MS (Table 5.2) using an optimized stepwise elution gradient. In total, 35.4 mg of more than 99% pure and 
39.7 mg of 95 to 98.9% pure rytvela (5.1.1) were synthesized. Noteworthy, these two rytvela samples possessed 
a crystalline solid state rather than the usual amorphous fluffy solids observed for the Elim (5.9) and crude 101.10 
samples (5.10).  
Entry Peptide 
Crude 
purity 
%
a
 
Purity 
%
a
 
Yield 
%
b
 
HRMS
c
 
m/z 
(calcd) 
m/z 
(obsd) 
5.1 
D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-
NH2 
85 > 99 17.4 850.4781 850.4747 
5.2 D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 85 92 9.7 694.3770 694.3784 
5.3 D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-D-Ala-NH2 N/A 99 N/A 765.4141 765.4149 
5.4 
D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-D-
Ala-NH2 
70 95 14.2 921.5152 921.5171 
5.5 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-NH2 85 95 6.5 779.4410 779.4430 
5.6 L-Arg-L-Tyr-L-Thr-L-Val-L-Glu-L-Leu-L-Ala-NH2 71 94 11.8 850.4781 850.4778 
5.7 
D-Ala-D-Leu-D-Glu-D-Val-D-Thr-D-Tyr-D-Arg-
NH2 
74 95 11.3 850.4781 850.4753 
5.8 L-Ala-L-Leu-L-Glu-L-Val-L-Thr-L-Tyr-L-Arg-NH2 88 93 12.8 850.4781 850.4756 
Table 5.1. Yields and purities of GMP rytvela, Ret analogues and co-synthesized contaminating peptides. 
a
 RP-
HPLC purity at 280 nm. 
b 
Yields after purification by RP-HPLC are based on Fmoc loading test for Rink resin. 
c
 
HRMS values from the major protonated molecule, typically [M+H]
+
. 
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Peak tR (min.)
a
 Fraction A214 (a.u.)
b
 Specie
c
 
1 2.50 1-2 -0.11 injection peak 
2 5.70 4-5 +0.28 unidentified 
3 11.00 10-12 +0.07 unidentified 
4 13.25 14-16 +2.00 rytvela 
5 17.70 19 +0.18 ytvela 
6 23.65 25 +0.50 unidentified 
Table 5.2. RP-HPLC profile of the crude GMP sample of rytvela on a Synergi® RP-Polar column (80 Å, 4 µm, 
150 mmx 21.2 mm I.D.). Eluting conditions employed were a flow rate of 10.6 mL/min. and a linear gradient 
composed as: 0-5 min. at 5% B; 5-20 min. from 5% to 20% B; 20-25 min. at 20% B; then washing and 
reconditioning (solvent A: H2O + 0.1% FA; solvent B: MeCN + 0.1% FA). 
a
 Retention times of each peak. 
b 
Maxi-
mum peak absorbance at 214 nm. 
c
 Protonated specie identified by ESI-MS. 
 
Entry Peptide
a
 Counter-ion 
5.1.1 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 FA 
5.1.2 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 TFA 
5.1.3 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 OAc 
5.2.1 D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 FA 
5.2.2 D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-NH2 TFA 
5.3 D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-D-Ala-NH2 TFA 
5.4 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-D-Ala-D-Ala-NH2 TFA 
5.5 D-Arg-D-Tyr-D-Thr-D-Val-D-Glu-D-Leu-NH2 FA 
5.6 L-Arg-L-Tyr-L-Thr-L-Val-L-Glu-L-Leu-L-Ala-NH2 FA 
5.7 D-Ala-D-Leu-D-Glu-D-Val-D-Thr-D-Tyr-D-Arg-NH2 FA 
5.8 L-Ala-L-Leu-L-Glu-L-Val-L-Thr-L-Tyr-L-Arg-NH2 FA 
5.9 101.10 from ELIM Biopharmaceuticals TFA 
5.10 crude 101.10 from our GMP synthesis TFA 
Table 5.3. Salts of different purified analogues and of various sources of 101.10. 
 
5.2.2 Ion-exchange of rytvela 
 After purification on a preparative Synergi® RP-Polar column using eluting solvents containing 0.1% 
formic acid, the counter-anion of rytvela (5.1.1) was assumed to be formate. To exchange formate to 
trifluoroacetate (stronger ion-pairing agent) or acetate (weaker ion-pairing agent; Dai et al., 2005), two solid-
phase extraction methods were examined: ion-exchange and reverse-phase chromatography (Roux et al., 2008). 
The first method called mixed-mode cation exchange (MCX), relies on interactions between cations contained in 
the mobile phase and benzenesulfonate anion bound to a polystyrene (PS)/divinylbenzene (DVB) stationary 
phase. The peptide salt was loaded onto the resin, washed with neutral pH water to elute off any formate 
attached, and was eluted with the ammonium salt of the desired counter-ion: ammonium trifluoroacetate or 
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acetate. The eluated peptide bound to trifluoroacetate/acetate was then lyophilized. In practice, elution of rytvela 
on the MCX resin required, however, an excess of ammonium salt which could not be evaporated with the eluate, 
resulting in issues of isolating the desired peptide salt. In principle, this may be addressed by dialysis; instead, 
the reverse-phase chromatography method was explored.  
 This latter alternative method was performed on a C18 reverse-phase resin, which relies on the principle 
that relatively hydrophobic peptides stay bound to the stationary phase when the counter-ion is eluted with near 
100% aqueous mobile phase. Increasing the amount of organic solvent in the mobile phase containing a strong 
acid of the desired counter-ion (i.e. trifluoroacetic acid or acetic acid) elutes the peptide bound to the new 
counter-anion. The correct peptide salt is then isolated by freeze-drying. The C18 reverse-phase resin ion-
exchange method proved more efficient with rytvela, due to the use of voltatile acids instead of salts, as well as 
the relative strength of interactions between the C18 phase and the peptide compared to the electrostatic 
interactions between the MCX anion and the peptide cation.  
 Both methods comprised technical limitations, such as the loading capacity of the cartridge limiting the 
experimental scale, and the recovery of the desired salt precluded by the loss of some peptide bound tightly to 
the sorbent and/or eluted in the washing step. An alternative approache would be to purify the crude peptide on 
the preparative Synergi® RP-Polar column and use eluting solvents containing 0.1% TFA or AcOH, or using the 
same column to exchange the formate salt. However, these methods are not without inconveniences such as the 
use of a large quantity of solvent and material loss on the column.  
 
5.2.3 Capillary electrophoresis analysis of the relative amount of counter-anions 
 Capillary zone electrophoresis (CZE)  is a technique introduced in the 1960s to separate species based 
on their charge, frictional forces and hydrodynamic radius in the interior of a small capillary filled with an eletrolyte 
(Terabe et al., 1984). The resolution of ionic compounds by capillary electrophoresis will depend on the 
differential migration of analytes, called electrophoretic migration velocity (up), in an applied electric field. In the 
capillary bounded by two electrodes, the analyte is attracted toward the electrode of the opposite charge, at the 
same time as it is pulled by the electroosmotic flow (EOF). The balance of these forces determines the resolution 
between different species.  
 To separate peptides and proteins, capillary electrophoresis has emerged as a high-resolution technique 
(Messana et al., 1997; Kasicka, 2001), complementary to HPLC, because both techniques rely on different 
physicochemical properties. Capillary electrophoresis coupled to indirect UV-absorption detection has become an 
efficient and reliable method for the quantitation of small anions. In this indirect detection method, UV-absorbing 
co-ions are added in the electrophoretic buffer to provide background UV signal during elution of the UV-inactive 
anion, resulting in a negative absorbance peak. For example, sodium phthalate has been used as the UV-
absorbing background electrolyte and cetyltrimethylammonium bromide (CTAB) as the EOF modifier for 
distinguishing peptide acetates from trifluoroacetates (Sazelova et al., 2006).  
 The relative amounts of the three counter-ions in different samples of rytvela (5.1.1-5.1.3) were thus 
measured using a published indirect-UV detection CZE method for the quantification of trifluoroacetate (Little 
2007) and of acetate (Altria et al., 1997). Calibration curves for each anion were first constructed with 
concentrations ranging from 0.05 to 10 mM, using sodium trifluoroacetate, ammonium acetate and ammonium 
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formate as the corresponding salts. Representative examples of electropherograms were obtained for each salt 
(5.1.1-5.1.3; Figure 5.2). The CZE calibration results were conducted in triplicates, and characteristics such as 
elution time, area under the curve (AUC), and peak shape were reproduced with high precision. Formate 
exhibited the highest electrophoretic velocity, due to its small radius, large charge to mass ratio and strong 
limiting ionic conductivity (λ0, 69.3 S·cm
2
·mol
-1
; Cummings et al., 2009), whereas acetate showed the slowest 
migration, possibly due to its weaker negative charge and limiting ionic conductivity (40.9 S·cm
2
·mol
-1
; Cummings 
et al., 2009). The median velocity of trifluoroacetate may be explained by its averaged higher limiting ionic 
conductivity (approximated between 26.37 and 72.65 S·cm
2
·mol
-1 
by several methods; Miyauchi et al., 1992) and 
stronger negative charge relative to acetate. These results demonstrated the reliability and the quality of 
resolution of the different anions, promoting the use of this method for quantifying the relative amount of each 
anion in different salts of the D-heptapeptide rytvela, as prepared above.  
 
Figure 5.2. Representative CZE electropherograms of 2.0 mM solutions of NH4OAc (a), NH4FA (b), and NaTFA 
(c), recorded with a BGE composed of 5 mM KHP, 50 mM MES, and 0.5 mM TTAB. 
 Although the exact ratio of counter-ion over peptide could not be determined and the electrophoretic 
mobility of the counter-ions slightly changed due to ion-pairing effect of the peptide, the CZE electropherograms 
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of the three salts of rytvela (Figure 5.3) reproducibly provided relative purity of the salt form. The presence of 
about 5% of formate and 15% of unidentified species was found in the acetate salt. Only trifluoroacetate was 
detected in the TFA salt sample. Around 10% of trifluoroacetate was noticed in the formate sample. As 
quantified, the samples were used to examine the influence of counter-ion on the bioactivity and conformation of 
rytvela. 
 
Figure 5.3. CZE electropherograms of different rytvela salt samples (acetate (a), formate (b), and trifluoroacetate 
(c)), recorded with a BGE composed of 5 mM KHP, 50 mM MES, and 0.5 mM TTAB. 
 
5.3 Conformation and biological activity of analogues 
5.3.1 Aggregation and solvent effects 
 Indications of aggregation at high concentration were obtained in the course of the synthesis of rytvela, 
when efforts were unsuccessful in dissolving the bulk of crude peptide after precipitation with ether. Aggregates 
may form in proteins or peptides by non-native intermolecular hydrophobic interactions, between unburied 
hydrophobic amino acid stretches. Aggregation, contrarily to folding, is a second or higher-order process, which 
is favoured at higher concentration. Constituted of hydrophobic amino acids (Tyr, Thr, Val, Leu, Ala), rytvela may 
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aggregate prior to folding or interaction with surrounding molecules at high concentrations. The extent of 
aggregation was determined by measuring the far-UV-CD curve of rytvela at aqueous concentrations ranging 
from 1 to 100 µM (Figure 5.4a). In addition, the structure-inducing solvent trifluoroethanol (TFE) (Sonnichsen et 
al., 1992) was employed to study the extent of rytvela folding in an alternative environment (Figure 5.4b). The CD 
curves of the present study were compared to electronic transition band values and backbone torsion angles of 
ideal secondary structures (Table 5.4).  
 
Figure 5.4. CD curves of rytvela formate salt (5.1.1) at different aqueous concentrations (a) and in different 
solvents at a concentration of 20 µM (b).  
Secondary 
structure 
Transition bands (nm) Dihedral angles (º) 
π0  π* π1  π* n  π* ϕi+1 ψi+1 ϕi+2 ψi+2 
random 
coil 
- 195  - 
+ 215-
230 
 -  -  -  - 
PPII helix - 205  - + 228 - 75 145  -  - 
Type I’ β-
turn 
- 190 + 202 + 220 60 30 90 0 
Table 5.4. Electronic transition bands and backbone dihedral angles of random coil and ideal left-handed PPII 
helix (Adzubei et al., 1993; Hutchinson et al., 1994; Rucker et al., 2002). 
 In spite of the intensity differences, the curve shapes at concentrations of 20 and 30 µM displayed the 
same maxima at 198 nm and a negative shoulder at 230 nm, suggesting that rytvela adopted disordered 
structure at those concentrations. At 50 and 100 µM, the positive maximum shifted from 198 to 202 and to 205 
nm, respectively. Moreover, at these higher concentrations, a negative maximum at 230 nm and a positive 
shoulder at 220 nm were observed, suggesting a PPII helical conformation. The changes in curve shape and 
increase in ellipticity at 50 and 100 µM may thus be due to aggregation of the peptide in solution (Sahin et al., 
2011). This hypothesis was supported by the predicted aggregation propensity of rytvela, which was performed 
using the widespread software AGGRESCAN (Sánchez et al., 2005; Conchillo-Sole et al., 2007) and Tango 
(Fernandez-Escamilla et al., 2004). In a first instance, the computational analysis from AGGRESCAN identified 
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the portion Thr-Val-Glu-Leu as the aggregation hot spot in 101.10, and estimated the aggregation potential at 
12% (data not shown). The Tango algorithm has predicted that the cross-β aggregation tendency of the 
sequence rytvela, in conditions ressembling that of the recording of the CD spectrum (pH = 7.0, T = 298.15 K, I 
(ionic strength) = 0 M), was 64.96.   
 Raman and IR spectroscopy could provide additional information about aggregation of the peptide 
(Barth et al., 2007) by probing the amide I vibrational bands; however, due to overlap of this band with that of 
water and to the clustering of various substrucures absorption bands in the spectral region of 1620-1680 cm
-1
, 
only qualitative information can be collected from such studies (Byler et al., 1986). Alternatively, 
1
H-NMR 
methods, which compares the differences in chemical shifts of the amino protons at different concentrations, 
have been used, but necessitate significant amount of material. Nuclear Overhauser effect spectroscopy 
(NOESY) experiments have equally been employed to study aggregation by surveying the change in secondary 
structures adopted by peptides in organic solvents; however, such NMR technique may be complicated because 
of the existence of in-solution conformational averaging (Jardetzky, 1980) and the need to use a model structure 
to resolve the diagnostic NOE crosspeaks (Blanco et al., 1993). Nonetheless, issues regarding the insufficient 
quantities available to do the spectroscopic studies, the dryness of the peptide and the lack of model molecules 
precluded the prompt use of Raman, IR, or NMR techniques to examine more deeply the aggregation of rytvela.  
 The CD spectra of rytvela in water and trifluoroethanol are distinct (Figure 5.4b): the former suggests a 
disordered structure, whereas the later indicates a turn motif, with two positive maxima at 202 and 225 nm (Table 
5.4). TFE is considered to exhibit helix- and turn-stabilizing effects by a general solvation effect and by 
destabilization of the coil state, due to less effective hydrogen bonding with the peptide amide bonds. 
Consequently, in TFE, rytvela may solvate better, and adopt different low-energy conformation. The change in 
conformation in a more lipophilic solvent may also reflect what may happen to the peptide in a biological 
environment.  
 
5.3.2 Conformational analysis  
 Although salts have been shown to affect the free energy and conformation of peptides (Nandi et al., 
1972), the CD curves did not differ significantly for the different salt forms of rytvela (5.1.1-5.1.3; data not shown), 
suggesting that the counter-anion had no detectable effect on the conformation of the peptide in a 20 µM 
solution. Studies have demonstrated that counter-ions may induce greater conformation stabilization effects at 
higher concentrations (Dempsey et al., 2011); however, such influence of concentration could not be tested on 
rytvela due to insufficient quantity of the TFA and acetate salts (5.1.2 and 5.1.3, respectively).  
 Far-UV-CD spectroscopy was used to compare the different aqueous conformations of rytvela  
analogues (5.1-5.8; Figure 5.5). The CD spectra of all the analogues relating to contaminating entities of crude 
101.10 (5.2-5.5; Figure 5.5a) all closely ressemble that of rytvela, indicating that addition of a C-terminal alanine, 
removal of the arginine and alanine residues, respectively, had no profound effect on conformation. Divergent 
bioactivity of such analogues would thus not be due to the difference in aqueous conformations. The CD spectra 
of the enantiomer RYTVELA (5.6), and the retro-enantio analogue ALEVTYR (5.8), both exhibited curves of 
opposite ellipticity and equal magnitude as rytvela (5.1.1) and the retromer alevtyr (5.7).  
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Figure 5.5. CD spectra of rytvela (5.1.1), co-synthesized contaminating peptides (5.2-5.5; a) and retro-enantio 
analogues (5.6-5.8; b). 
 
5.3.3 Biological activity  
 Biological activity of the different rytvela salts and analogues (5.1-5.8) was determined using the HEK 
Blue reporter gene and fluodye intercalation assays, measuring the inhibition of IL-1β-induced NF-κB/MAPK 
activation and thymocytes proliferation, respectively (Figure 5.6). In these assays, kineret, the competitive IL-1R 
antagonist, blocked completely the induction of NF-κB/MAPK pathways by both exogenous and endogenous IL-
1β, and reduced stimulated proliferation by about two thirds. In both assays, the formate (5.1.1) and 
trifluoroacetate (5.1.2) forms of rytvela exhibited comparable, relatively poor inhibitory activity, which was later 
corroborated by in vivo studies in which both salts failed to significantly diminish the IL-1β-induced hyperthermia 
in rats (data not shown)
1
*. On the contrary, the 101.10 sample originating from Elim Biopharmaceuticals (5.9) 
displayed one of the strongest IL-1β blockades of proliferation and pathway induction, albeit with a large SEM 
that may originate from inhomogeneity of the material. A similar strong effect was reproduced in the NF-κB/MAPK 
test using a crude sample of rytvela (5.10) synthesized in our laboratories. The trifluoroacetate salts of ytvela, 
ytvelaa and rytvela (5.2.2, 5.3-5.4), the three most common contaminating peptides found in crude rytvela, all 
demonstrated relatively high levels of IL-1β inhibition. Truncating rytvela at its N-terminus produced an 
hexapeptide (5.2) that displayed improved activity for both salts in the HEK Blue assay, and for the TFA salt 5.2.2 
in the CyQUANT test, compared to rytvela. Removing the C-terminal residue (5.5) had a profound influence on 
the anti-inflammatory effect of the peptide, where it lost 80% of its inhibitory efficacy. However, the same deletion 
had only a modest effect (loss of 23% activity relative to 5.1.1) in thymocyte proliferation, as previously reported 
for this analogue (Chemtob et al., 2005). These results underline the relative importance of both terminal 
residues (D-Arg
1
 and D-Ala
7
) to impart the desired bioactivities. 
                                                          
* These in vivo IL-1β-induced hyperthermia experiments were performed by Dr. Xin Hou, according to procedures described in the literature 
(Quiniou et al., 2008).  
Chapter 5 77 
 
 Interleukin-33 (IL-33), a related IL-1 family member, shares the same accessory protein (IL-1RAcP) as 
IL-1, and binds to a receptor, termed IL-1 receptor-like 1 (IL-1RL1, or ST2), that possesses considerable 
resemblances to IL-1R. The HEK Blue cells used in the reporter gene assay also express the IL-1RL1 at their 
surface, such that using exogenous amounts of IL-33 to trigger the NF-κB/MAPK cascade in peptide-treated HEK 
Blue cells, the IL-1/IL-33 selectivity of rytvela and analogues may be tested. For most analogues (data not 
shown), no influence on the IL-33 stimulation was detected, except for all TFA salts (5.1.2, 5.2.2, 5.3 and 5.4) 
that induced an average of 7-10% inhibition of the IL-33 effect compared to kineret and rytvela formate (no 
effect). Thus, this inhibition of trifluoroacetate on IL-33-mediated activation of inflammatory cascades may 
account for the differences observed between various salts in the IL-1β-dependent assay. In other words, it may 
be hypothesized that trifluoroacetates are less specific than their formate counterparts; but a deeper examination 
of the pharmacological profiles of ytvela, ytvelaa and rytvelaa (5.2-5.4) is in order to itemize their specificity and 
efficacy and that of their various salts. 
 
Figure 5.6. Inhibition of IL-1β-induced thymocyte proliferation (a) and NF-κB/MAPK activation (b) by rytvela, salts 
(5.1.1 and 5.1.2) and analogues (5.2-5.4, 5.9-5.10), as assessed by fluodye intercalation and HEK Blue reporter 
gene assays, respectively. Sample bars correspond to cells that were stimulated by an exogenous amount of hIL-
1β. Data are plotted as percentage of inhibition of IL-1β-induced effect and reported as mean value ± SEM. 
 In the same in vitro assays, the formate salts of the Ret analogues (5.6-5.8; Figure 5.7) produced 
significantly weaker inhibitory activity than rytvela (5.1.1). The Ret derivatives unanimously inhibited 61% of the 
NF-κB/MAPK activation, and exacerberated the IL-1β-stimulated proliferation of immune cells. The retro and 
retro-enantio derivatives exhibited the stronger (40% and 32%, respectively) increase in proliferation, suggesting 
that sequence has a profound effect on anti-proliferative activity.  
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Figure 5.7. Inhibitory activity of rytvela and Ret analogues (5.6-5.8) on IL-1β-induced NF-κB/MAPK activation (a) 
and thymocyte proliferation (b). Data are plotted as percentage of inhibition of IL-1β-induced effect and reported 
as mean value ± SEM. 
 
5.4 Concluding remarks 
 Employing CD and biological analyses provided additional information on the importance of counter-ion, 
purity, and sequence for rytvela activity. Although the counter-ion had no pronounced effect on conformation as 
observed by the similarities in the CD curves of the different rytvela salts, trifluoroacetates (5.1.2 and 5.2.2) 
exhibited somewhat better anti-IL-1β activity than formate salts in the in vitro biological assays of rytvela and 
ytvela. These results were also corroborated by in vivo hyperthermia experiments conducted with pure salts. 
Crude samples of 101.10 (5.9-5.10) consistently presented higher inhibitory effects than purified rytvela (5.1). 
Trifluoroacetate salts of co-synthesized contaminating peptides (i.e., ytvela, rytvela, ytvelaa, 5.2-5.4) detected in 
crude 101.10 samples exhibited improved anti-IL-1β activity relative to pure rytvela, yet produced analogous CD 
spectra. Ret analogues 5.6-5.8 engendered CD curves indicative of a disordered structure, and diminished 
bioactivity compared to rytvela, especially in the thymocyte proliferation assay, in which they augmented IL-1β 
stimulation by 18 to 40%.  
 
Figure 5.8. Structure-activity relationships observed for the Ret analogues, co-synthesized contaminating 
peptides and salts of 101.10. 
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 More experiments should be conducted before speculating on the effects of the counter-ion on rytvela 
behaviour. Various screening techniques may be needed to select the ideal salt for the desired pharmacological 
profile (Berge et al., 1977), taking into consideration practical details such as the cost of raw materials, and the 
ease of preparation and purification. For example, trifluoroacetates generally facilitate HPLC purification by 
notably suppressing ion-exchange side effect with uncapped silanol groups on the RP-HPLC packing (Bennett, 
1991), are volatile, stick more firmly to the peptide as classified in the Hofmeister series, and are FDA-approved 
pharmaceutical salts (Gould ,1986); yet their environmental impact (Boutonnet et al., 1999) and toxicity to aquatic 
organisms (Berends et al., 1999) limit their use as counter-ion. Salt selection guidelines (Berge et al., 1977; 
Kerns et al., 2008) advocate the use of counter-ions that have a pKa differing from the drug by only 2-3 units, 
which is not the case for TFA. In this perspective, the formate (pKa = 3.75) and acetate (pKa = 4.75) salt forms 
may be preferred.  
 
5.5  Experimental section 
5.5.1 General 
 See experimental section of chapter 2. 
 
5.5.2 Solid-phase peptide synthesis 
 See experimental section of chapter 2. 
 
5.5.3 SPPS according to Good Manufacturing Practices 
 Optical purity of Fmoc-D-amino acids was assessed by measurement of their specific rotation at the 
sodium D line (as previously described, chapter 2), at a concentration of 1.0 g/100 mL in either DMF or EtOAc. 
Iso-propanol and di-iso-propylether were used in the washing and precipitation steps, instead of their shorter 
alkyl equivalents, methanol and ethyl ether, due to their lower volatility and hygroscopicity. New or argon-sealed 
bottles of reagents and solvents were employed. Weight measurements were conducted on a manually 
calibrated analytical balance (Denver PI-225D; Denver Instruments, Bohemia, USA), and volumes were 
measured with Becton-Dickinson seringes (BD Biosciences, Mississauga, Canada) or recently calibrated variable 
volume Eppendorf Research® pipettes (Eppendorf, Mississauga, CA). HPLC-MS purity analyses and preparative 
RP-HPLC purification of the peptide samples were conducted using a Synergi® RP-Polar column and an 
optimized elution gradient (0-5 min. at 5% solvent B, 5-20 min. at 5-22% solvent B, 20-25 min. at 20% solvent B, 
25-27 min. 20-95% solvent B, followed by column washing and reconditioning; solvent A: H2O + 0.1% FA or TFA; 
solvent B: MeCN + 0.1% FA or TFA) which efficiently resolved the desired product peak from the secondary 
peaks. Crude and purified peptide samples were lyophilized in separate instruments, at 101 mTorr and -86°C. 
 The GMP procedure for SPPS of rytvela is in essence the same as that reported for standard SPPS 
protocol, except of the following changes: the loading of the resin was determined twice with parallel 
methodologies; the peptidic scale used was 0.3 mmol; Kaiser tests were performed after each step and repeated 
in case of intermediate outcome; all amino acid couplings were carried for 1 hour with 2.5 equiv. of each DIEA, 
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HBTU and Fmoc-D-amino acid before being tested for completion, and in the negative, restarted for 1 hour with 
fresh coupling medium.  
 
5.5.4 Characterization and purification 
 Refer to experimental section of chapter 2. 
  
5.5.5 Ion-exchange chromatography 
 Oasis® MCX 3cc cartridges (1 meq/g, 60 µm, 80 Å; Waters Corp., Milford, USA) were conditioned with 
anhydrous MeOH (1 mL) and equilibrated with Milli-Q H2O (1 mL) before the peptide solutions (ranging from 5 to 
10 mM) were loaded. Solvents and samples were passed through the cartridges dropwise. The cartridges were 
washed with water containing 2% formic acid (2 mL). Then, the adsorbed compounds were ion-exchanged and 
eluted from the MCX cartridges with 2 x 1 mL H2O containing 5% NH4TFA or NH4OAc followed by  2 x 1 mL 
MeOH. Eluates were recovered in 10 mL glass test tubes and lyophilized for subsequent analysis. 
 
5.5.6 Reverse-phase chromatography 
 The counter-anions of peptide samples were exchanged using solid-phase extraction (SPE) C18 
column, which is analogous to that used for reverse-phase HPLC chromatography. Essentially, SPE-driven ion-
exchange was carried out using 1 mL cartridges packed with 100 mg of AccuBOND
II 
octadecylsilane (ODS)-C18 
sorbent (Agilent Technologies, Mississauga, CA). The cartridges were conditioned by passing 1 mL of anhydrous 
MeOH, and equilibrated with 2 portions of 1 mL of H2O:ACN 95:5 containing 0.1% TFA. Peptide solutions (100 
µL, concentrated at 20 mM) were loaded on the cartridges at a flow rate of one drop per second (3-5 mL/min.) 
using controlled argon flow. The cartridges were washed with 1 mL of H2O:MeCN 95:5 containing 0.1% TFA, 
then eluted with 2 portions of 1 mL of H2O:MeCN 20:80 containing 0.1% TFA followed by 1 mL of dry MeCN. 
Eluates were collected in 10 mL glass tubes and freeze-dried for further analysis. 
 
5.5.7 Capillary zone electrophoresis 
 Relative quantities of the different counter-anions contained in peptide samples were determined, as 
previously described (Little et al., 2007) by capillary zone electrophoresis (CZE) using a G1600AX system 
(Agilent Technologies, Mississauga, Canada) equipped with a diode array UV-detector monitoring at 350 nm, 
with background signal set at 254 nm. All separations were performed at 25C in a bare fused silica capillary 
(Polymicro Technologies, Phoenix, USA) of 54 cm total length and 44 cm effective length (to the detector), with 
dimensions of 75 μm I.D. x 360 μm O.D. The applied voltage was -20 kV and the background electrolyte (BGE) 
was 5 mM potassium hydrogen phthalate, 50 mM methylester sulfonate (MES), 0.5 mM 
tetradecyltrimethylammonium bromide (TTAB), adjusted to pH 5.0 with 0.1 M HCl. Between each injections and 
separations, the capillary was rinsed at 34.5 mbar with 1.0 M NaOH for 2 min., Milli-Q H2O for 2 min., 1.0 M HCl 
for 2 min, 0.1 M HCl for 2 min., and finally with BGE for 2 min. Injection of 20 nL of sample solution (ranging from 
0.1 to 10 mM in 100% H2O) was accomplished by application of 34.5 mbar for 16 s and then BGE for 2 s at the 
inlet end of the capillary. Relative amounts of counter-ions were determined by calculating the area under the 
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curve (AUC) of corresponding peaks, relative to signal-to-noise of the background signal. Each separation was 
repeated three times, and elution times are reported in min.  
 
5.5.8 Ultraviolet-circular dichroism 
 Similar to the experimental section of chapter 2, except that different aqueous concentrations of rytvela 
formate salt were used (20, 30, 50, and 100 µM). The CD spectrum of 20 µM of rytvela formate was recorded in 
TFE, after TFE blank signal was subtracted.  
 
5.5.9 Biological activity screening via fluodye intercalation and HEK Blue reporter gene assays 
 Same as experimental section of chapter 2. 
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6.1  Conclusion 
 As one of the major pro-inflammatory mediators in humans, IL-1β participates in numerous intracellular 
pathways upon binding to its receptor (IL-1RI), which leads to severe immune disorders and acute bouts of 
inflammation (Dinarello, 2011). Current anti-IL-1β approaches under development involve recombinant natural 
antagonists, monoclonal antibodies, fusion proteins and small organic molecules (Dumont, 2006). Kineret® (IL-
1Ra) is the only product fully approved so far that selectively targets IL-1β by competing with the latter for 
receptor binding. Inconveniences of this daily administered compound include poor bioavailability, 
immunogenicity, increased susceptibility to infection, short half-life and high costs. Small molecule inhibitors of IL-
1RI would offer a prolonged duration of action, a good enteral bioavailability, and be hopefully more affordable. 
Such a major breakthrough for IL-1R antagonists remains a clear and unmet medical need. The D-heptapeptide 
101.10 (rytvela) has demonstrated features of a negative allosteric modulator and exhibited high potency and 
efficacy in blockade of various IL-1β-mediated effects both in vitro and in vivo. However, considering that 
peptides do not generally possess sufficient “drug-like” properties which allow them to efficiently cross 
physiological barriers, one of the objectives of the present studies was to develop peptidomimetics of 101.10 
which display improved anti-IL-1β efficacy and optimal physicochemical properties.  
 In order to explore the relationships between peptide composition, conformation and biological activity, 
different series of analogues were synthesized and examined to understand the factors influencing the inhibitory 
actions of the peptide 101.10 on IL-1β. Common peptidomimetism strategies were employed to probe the 
pharmacophores of 101.10, which include: rigid scaffold such as amino-γ-lactams, indolizidinone amino acids 
and proline; N- and C-terminal truncations; substitution by analogous amino acids; and sequence and chirality 
inversions.       
The synthesis and evaluation of a library of α- and β-amino-γ-lactam analogues of 101.10 (Jamieson et 
al., 2009; Boutard et al., 2011) showed that higher bioactivity was generally exhibited by the (R)-Agl and (S)-Bgl 
series, relative to their enantiomeric counterparts, suggesting that these complementary lactams may adopt 
similar conformational space. Position-dependent bioactivity was also observed in scanning the sequence with 
the different amino-γ-lactams. For example, replacement of D-Arg
1
 for (R)-Agl
1
 produced an analogue exhibiting 
the best anti-proliferative effect, whereas substitution of D-Thr
3
 and D-Val
4
 for Agl and Bgl residues showed that 
although IL-1β inhibition was maintained, lower efficacy was observed in the 3-position relative to the 4-position. 
Results from the applications of amino-γ-lactams raised questions concerning the trade-off or the loss of 
side-chain function for the gain in conformational restriction. When the chirality was exchanged at Thr
3
-Val
4
, 
divergent behaviours were observed relative to inhibition of IL-1β-mediated thymocyte proliferation and NF-
κB/MAPK pathways activation; suggesting that these peptidomimetics exhibited functional selectivity towards the 
IL-1RI. Using α-amino-β-hydroxy-γ-lactams as constrained Thr
3
 mimetics, the importance of side-chain versus 
stereochemistry versus conformation was probed. For example, peptides containing a L-Thr
3
 or a (3S)-Hgl
3
 
demonstrated improved inhibition of immune cell proliferation over rytvela (5.1) and (R)-Agl
3
 (2.8); and derivatives 
including a L-Val
4
 or a (3R)-Hgl
3
 exhibited retained blockade of NF-κB/MAPK compared to rytvela, but lower 
relative to [(R)-Agl
3
]-101.10. Moreover, substitution of D-Thr for either L- or D-Val resulted in reduced activity, 
supporting the importance of the hydroxyl group for blockade of IL-1β.   
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 The D-Thr
3
-D-Val
4
 residues were then replaced by indolizidin-2-one amino acids of different 
stereochemistry. Although [(3R,6R,9R)-I
2
aa
3,4
]- and [(3S,6S,9S)-I
2
aa
3,4
]-101.10 (4.20 and 4.24) had respectively 
little influence on IL-1β effects, [(3R, 6R, 9R)-I
2
aa
3-4
, ΔAla
7
]-101.10 (4.19) exhibited the strongest inhibitory 
efficacy of the examined series in both assays. In comparison, [D-Pro
4
]-101.10 presented high anti-IL-1β activity, 
contrary to its C-truncated counterpart. The biological data of the mimetics bearing respectively lactam residues 
(Agl/Bgl and I
2
aa) and proline supported the importance of D-amino acid stereochemistry in the Thr
3
-Val
4
 region 
for imparting activity.  
 Retro-, enantio- and retro-enantio isomers were then prepared as to probe the influence of sequence 
directionality and side-chain configurations on the global conformation and bioactivity of 101.10.  Relative to 
rytvela, all retro-enantio analogues respectively exacerbated and slightly inhibited IL-1β-induced immune cell 
proliferation and inflammatory pathways induction, confirming the appropriate sequence direction and global 
side-chain chirality of the D-sense heptapeptide rytvela.  
 Exchanging counter-anion had limited influence on the CD spectrum of rytvela, but influenced the 
capacity to block IL-1β in vitro: trifluoroacetates consistently displayed stronger inhibition of cell proliferation and 
downstream signaling activation than acetates and formates. This effect may be due to the weaker selectivity of 
the trifluoroacetate salts towards the homologous cytokine IL-33. The purity of the 101.10 samples was 
demonstrated to be of high impact. Commercial samples (5.9 and 5.10) were shown to contain significant 
contaminants and exhibited stronger inhibition of IL-1β effects relative to purified rytvela, raising interest in the 
inividual activity of contaminants. For example, the truncated sequences ytvela and rytvel demonstrated 
respectively a significant loss in potency and retained activity, comparable to that of other commonly found 
impurities such as rytvelaa and ytvelaa.  
 Attempts to restrict the parent peptide resulted in changes from random coil to ordered structure as 
observed by CD spectroscopy. For example, the majority of Agl and Bgl analogues displayed CD curves 
suggestive of type I and II’ β-turns, which possess similar torsional angles. The most active (3S,4R)-Hgl analogue 
exhibited a spectrum characteristic of a type I β-turn. Indolizidin-2-one analogues showed indications of 
polyproline-like helical structure and the proline-containing peptides exhibited CD data characteristic of a type I β-
turn. In addition, certain Thr
3
-Val
4
 diastereomeric analogues exhibited β-fold CD spectra, which corresponded to 
turn types of comparable configurations in Hgl
3
 mimetics. Alternatively, the different salts of 101.10, the retro, 
retro-enantiomeric and enantiomeric isomers, as well as the truncated peptides, all demonstrated unanimously 
curves similar to that of rytvela. Taken all together, the spectroscopic and biological data highlights the 
importance of peptide folding to elicit improved activity at the IL-1R complex. 
 In brief, guidance has been gained from the clustering of analogues that exhibited CD curves 
characteristic of folding motifs and improved activity towards optimization of the lead peptide. For example, 
peptidomimetics that displayed improved anti-proliferative activity relative to rytvela possessed CD curves 
indicative of either a type I or II’ β-turn. Analogues that exhibited stronger blockade of IL-1β-mediated 
inflammation compared to rytvela produced CD spectra suggestive of type I and type II’ β-folds. Finally, the few 
compounds that superiorly inhibited both IL-1β effects demonstrated absorption bands characteristic of type I β-
turn and polyproline type II helical structures. As ideal ϕ and ψ dihedral angles for β-turns of type I and II’ and that 
of poly-D-proline of type II are similar to each other (Tables 3.3 and 4.1), all these conformers exist in a dynamic 
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equilibrium, in which a slight change in rigidification or configuration may favour one conformer over the others. It 
is the relative amounts of these conformers that emerge in aqueous CD spectoscopy. 
 To conclude, the compilation of SARs has served to elaborate four main aspects of the project: 1) crude 
samples are more active than purified rytvela both in in vitro and in vivo tests, suggesting there may be an effect 
of counter-anion or an unidentified contaminant; 2) several peptidomimetics exhibited functional selectivity 
towards IL-1β-mediated immune and inflammatory responses, an important features of IL-1RI allosteric 
modulators; 3) identification of some pharmacophore elements in the parent peptide, highlighted the importance 
of the hydroxyl in Thr
3
 side-chain, and of the D-stereochemistry at 3- and 4-positions; and 4) discovery of a new 
lead (4.19), which displayed improved efficacy in both cellular assays relative to rytvela. 
 
6.2  Perspectives 
 Peptidomimetics discussed in the present studies possessed notable advantages over 101.10: they 
have been produced in high purity and bound to a known counter-anion; they may display improved selectivity 
and efficacy due to their reduced flexibility; and they can be accessed through straightforward and 
stereoselective synthetic approaches. In an effort to better understand how 101.10 exerts its biological effect 
upon binding to IL-1RI, the new lead mimetic [(3R,6R,9R)-I2aa
3,4
, ΔAla
7
]-101.10 (4.19) could be further 
characterized and developed. Assessment of the in vivo efficacy of this analogue could be performed in murine 
models of IL-1β-induced hyperthermia and PMA-mediated contact dermatitis, which would validate the in vitro 
activities observed. Subsequently, the new lead could be further optimized towards improving bioavailability and 
efficacy versus toxicology, by: alkylating the 4-position of the I
2
aa bicycle to probe the need of hydroxyl group 
with this particular scaffold; choosing amino acids that have been shown to be unimportant for antagonistic 
activity, and use their side-chain to construct cyclic structures and lock a portion of the mimetic into a fold of a 
pre-defined size; or replace these superfluous residues by constrained derivatives, such as trimethyltyrosine 
(TMT) and cyclovaline (c3Val); performing amide bond isosteric replacement (see chapter 1); substituting an 
internal residue for glycine or a constraining moiety such as α,α-dialkyl amino acids (see chapter 1). Additionally, 
permeability of the lead could be enhanced by the addition of hydrophobic entities or alteration of polar groups, 
such as substitution of D-Tyr for D-cyclohexylalanine (Cha) or of D-Glu for D-2-amino-4-phosphonobutanoic acid 
(AP4), or by choosing a lipophilic counter-anion such as phosphate or nitrate (Takacs-Novak et al., 1999; 
Sarveiya et al., 2005). 
 In addition, although the agonistic analogues (IL-1β stimulatory agents) of 101.10 have not been widely 
discussed due to the opposite nature of their effects, they may be potentially used as bacterial adjuvants to 
achieve immunostimulation against host infection (Dumont, 2006) or as study tools for extended IL-1-related 
diseases such as brain ischemia (Boutin et al., 2001), cardiovascular inflammatory conditions (Bujak et al., 2009; 
Fearon et al., 2008), and type 2 diabetes (Donath et al., 2011).  
 In a more distant instance, future efforts toward the advancement of this project may englobe a deeper 
examination of: the aggregation pattern of rytvela using deconvoluted FT-IR, Raman and NMR with a model 
peptide (Blanco et al., 1993); the effect of different salts on the in vitro and in vivo biology of rytvela, as well as 
the stability, crystallinity, morphology and hygroscopicity of the salt form, allowing to choose the proper counter-
ion for subsequent librairies of analogues; the dynamic conformation, as well as the extent of PPII/random 
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coil/turn equilibrium, for rytvela and selected analogues by high-resolution magic angle spinning (Sarkar et al., 
1996; Furrer et al., 2001) or 2D-NMR techniques (Ferentz et al., 2000); and computational docking and virtual 
screening using improved homology models of IL-1RI/IL-1RAcP complex.  
 Such computational avenues have already been undertaken for a long time, but have been drastically 
complicated by the lack of crystal data on the whole receptor complex and by the relatively poor fit of the 
homology models for transmembrane receptors (Wong et al., 2011). Because the “RYTVELA” (all L-amino acids) 
sequence lays in the juxtamembranal portion of IL-1RAcP, more precisely at 1 residue from the membrane, the 
interface peptide 101.10 is not expected to bind at the crystallisable extracellular portion of IL-1RI (316 amino 
acids; commercially available), since the section that usually interacts with IL-1RAcP is not included in the 
ectodomain. However, considering that mimics may interact at a distinct site on the receptor than the parent 
101.10, surface plasmon resonance (SPR) binding studies could be conducted with the cytosolic portion of the 
IL-1RI and IL-1RAcP, using a method previously described in the literature (Wang et al., 2010).     
 Although some efforts have been made to crystallize enantiomerically pure and racemic mixtures of 
rytvela, no X-ray diffraction-suitable crystals have been obtained at this time. However, attempts to crystallize 
rytvela either alone or bound to the IL-1R may be more successful by employing crystallization screening 
techniques (some are even automatized HTS method; Rupp, 2007), such as Grid Screen® (McPherson, 1999), 
Footprint screening (Stura et al., 1992) and stochastic CRYSTOOL® sampling (Segelke, 2001), in which a 
collection of different solvents, buffers and pH are used to find the optimal crystallization conditions for your 
sample. Such high-resolution crystal structures of the heptapeptide may unveil novel information regarding the 
prevalent conformers (e.g. among type I and II’ β-turns, random coil and PPII) when free and receptor-bound, 
which in turn could contribute to the future rational-based design of mimics. 
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